Medtronic plc - FORM 10-Q - September 7, 2016

Attached files

file	filename
EX-32.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 906 - Medtronic plc	mdt-2017q1xex322.htm
EX-32.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 906 - Medtronic plc	mdt-2017q1xex321.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 203 - Medtronic plc	mdt-2017q1xex312.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 203 - Medtronic plc	mdt-2017q1xex311.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q



x	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 29, 2016

Commission File Number 001-36820



MEDTRONIC PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)

Ireland	98-1183488
(State of incorporation)	(I.R.S. Employer Identification No.)

20 On Hatch, Lower Hatch Street

Dublin 2, Ireland

(Address of principal executive offices) (Zip Code)

+353 1 438-1700

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer x		Accelerated filer o
Non-accelerated filer o		Smaller Reporting Company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

As of August 26, 2016, 1,381,935,603 ordinary shares, par value $0.0001, and 1,872 A preferred shares, par value $1.00, of the registrant were outstanding.

TABLE OF CONTENTS



Item	Description	Page

	PART I
1.	Financial Statements (unaudited)	1
2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	44
3.	Quantitative and Qualitative Disclosures About Market Risk	60
4.	Controls and Procedures	61
	PART II
1.	Legal Proceedings	62
2.	Unregistered Sales of Equity Securities and Use of Proceeds	62
6.	Exhibits	62
	Signatures	63

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

Medtronic plc

Consolidated Statements of Income

(Unaudited)



	Three months ended
(in millions, except per share data)	July 29, 2016			July 31, 2015
Net sales	$	7,166		$	7,274

Costs and expenses:
Cost of products sold	2,261			2,456
Research and development expense	556			558
Selling, general, and administrative expense	2,428			2,449
Restructuring charges, net	94			67
Certain litigation charges	82			—
Acquisition-related items	52			71
Amortization of intangible assets	487			481
Other expense, net	39			61
Operating profit	1,167			1,131

Interest income	(93		)	(115		)
Interest expense	272			306
Interest expense, net	179			191
Income from operations before income taxes	988			940
Provision for income taxes	59			120
Net income	$	929		$	820

Basic earnings per share	$	0.67		$	0.58

Diluted earnings per share	$	0.66		$	0.57

Basic weighted average shares outstanding	1,392.2			1,418.1

Diluted weighted average shares outstanding	1,407.1			1,436.4

Cash dividends declared per ordinary share	$	0.43		$	0.38

The accompanying notes are an integral part of these consolidated financial statements.

Medtronic plc

Consolidated Statements of Comprehensive Income

(Unaudited)



	Three months ended
(in millions)	July 29, 2016			July 31, 2015
Net income	$	929		$	820

Other comprehensive loss, net of tax:
Unrealized gain (loss) on available-for-sale securities, net of tax expense (benefit) of $52 and $(74), respectively	115			(131		)
Currency adjustment, net	(350		)	(26		)
Net change in retirement obligations, net of tax expense of and $2 and $10, respectively	25			13
Unrealized gain (loss) on derivatives, net of tax expense (benefit) of $30 and $(20), respectively	54			(28		)

Other comprehensive loss	(156		)	(172		)

Comprehensive income	$	773		$	648

The accompanying notes are an integral part of these consolidated financial statements.

Medtronic plc

Consolidated Balance Sheets

(Unaudited)



(in millions)	July 29, 2016			April 29, 2016
ASSETS

Current assets:
Cash and cash equivalents	$	3,060		$	2,876
Investments	9,750			9,758
Accounts receivable, less allowances of $161 and $161, respectively	5,357			5,562
Inventories	3,580			3,473
Other current assets	1,751			1,931
Total current assets	23,498			23,600

Property, plant, and equipment	9,917			9,714
Accumulated depreciation	(5,103		)	(4,873		)
Property, plant, and equipment, net	4,814			4,841
Goodwill	41,309			41,500
Other intangible assets, net	26,437			26,899
Tax assets	1,232			1,383
Other assets	1,311			1,421
Total assets	$	98,601		$	99,644

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current liabilities:
Current debt obligations	$	1,947		$	993
Accounts payable	1,615			1,709
Accrued compensation	1,205			1,712
Other accrued expenses	3,129			2,751
Total current liabilities	7,896			7,165

Long-term debt	30,124			30,109
Accrued compensation and retirement benefits	1,770			1,759
Accrued income taxes	2,344			2,903
Deferred tax liabilities	3,790			3,729
Other liabilities	1,785			1,916
Total liabilities	47,709			47,581

Commitments and contingencies (Notes 3 and 15)

Shareholders’ equity:
Ordinary shares— par value $0.0001	—			—
Retained earnings	52,848			53,931
Accumulated other comprehensive loss	(2,024		)	(1,868		)
Total shareholders’ equity	50,824			52,063
Noncontrolling interests	68			—
Total equity	50,892			52,063
Total liabilities and equity	$	98,601		$	99,644

The accompanying notes are an integral part of these consolidated financial statements.

Medtronic plc

Consolidated Statements of Cash Flows

(Unaudited)



	Three months ended
(in millions)	July 29, 2016			July 31, 2015
Operating Activities:
Net income	$	929		$	820
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	737			701
Amortization of debt discount and issuance costs	7			7
Acquisition-related items	(5		)	232
Provision for doubtful accounts	9			10
Deferred income taxes	32			(159		)
Stock-based compensation	79			96
Other, net	(85		)	(39		)
Change in operating assets and liabilities, net of acquisitions:
Accounts receivable, net	196			279
Inventories	(101		)	(207		)
Accounts payable and accrued liabilities	(361		)	(424		)
Other operating assets and liabilities	50			(408		)
Certain litigation charges	82			—
Certain litigation payments	(19		)	(92		)
Net cash provided by operating activities	1,550			816
Investing Activities:
Acquisitions, net of cash acquired	(12		)	(179		)
Additions to property, plant, and equipment	(330		)	(224		)
Purchases of investments	(1,044		)	(1,851		)
Sales and maturities of investments	1,104			1,266
Other investing activities, net	(2		)	2
Net cash used in investing activities	(284		)	(986		)
Financing Activities:
Acquisition-related contingent consideration	(11		)	(3		)
Change in current debt obligations, net	926			429
Issuance of long-term debt	33			—
Payments on long-term debt	(17		)	(1,004		)
Dividends to shareholders	(599		)	(538		)
Issuance of ordinary shares	214			98
Repurchase of ordinary shares	(1,763		)	(750		)
Other financing activities	57			24
Net cash used in financing activities	(1,160		)	(1,744		)
Effect of exchange rate changes on cash and cash equivalents	78			50
Net change in cash and cash equivalents	184			(1,864		)
Cash and cash equivalents at beginning of period	2,876			4,843
Cash and cash equivalents at end of period	$	3,060		$	2,979
Supplemental Cash Flow Information
Cash paid for:
Income taxes	$	115		$	636
Interest	68			76

The accompanying notes are an integral part of these consolidated financial statements.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

1. Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic or the Company) for the periods presented. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year.

Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended April 29, 2016.

The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation.

The Company’s fiscal years 2017, 2016, and 2015 will end or ended on April 28, 2017, April 29, 2016, and April 24, 2015, respectively.

2. New Accounting Pronouncements

Recently Adopted

In April 2015, the Financial Accounting Standards Board (FASB) issued accounting guidance that requires debt issuance costs to be presented in the balance sheet as a direct deduction from the related debt liability. Prior to this amendment, debt issuance costs were recognized as an asset in the balance sheet and did not offset the related debt liability. The Company retrospectively adopted this guidance in the first quarter of fiscal year 2017. Its adoption had an impact of $133 million and $138 million on the Company's consolidated balance sheets at July 29, 2016 and April 29, 2016, respectively.

Not Yet Adopted

In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019 using one of two prescribed retrospective methods. The Company is evaluating the impact of the amended revenue recognition guidance on the Company’s consolidated financial statements.

In January 2016, the FASB issued guidance which requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The guidance also includes a simplified impairment assessment of equity investments without readily determinable fair values and presentation and disclosure changes. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019. The Company is evaluating the impact of the equity investment guidance on the Company's consolidated financial statements.

In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. The guidance is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements and is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted. The Company is evaluating the impact of the lease guidance on the Company's consolidated financial statements.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

In March 2016, the FASB issued guidance to simplify the accounting for share-based payment transactions by requiring all excess tax benefits and deficiencies to be recognized in income tax expense or benefit in earnings; eliminating the requirement to classify the excess tax benefit and deficiencies as additional paid-in capital. For the three months ended July 29, 2016, the Company recognized $57 million of excess tax benefits in additional paid-in capital. Under the new guidance, an entity makes an accounting policy election to either estimate the expected forfeiture awards or account for forfeitures as they occur. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2018.

3. Acquisitions and Acquisition-Related Items

The Company had various acquisitions and other acquisition-related activity during the first quarter of fiscal years 2017 and 2016. Certain acquisitions were accounted for as business combinations as noted below. In accordance with authoritative guidance on business combination accounting, the assets and liabilities of the businesses acquired were recorded and consolidated as of the acquisition date at their respective fair values. Unless otherwise disclosed, the pro forma impact of these acquisitions was not significant, either individually or in the aggregate, to the results of the Company for the three months ended July 29, 2016 or July 31, 2015. The results of operations related to each business acquired have been included in the Company's consolidated statements of income since the date each business was acquired.

Fiscal Year 2017

The fair values of the assets acquired and liabilities assumed during the three months ended July 29, 2016 were as follows:



(in millions)
Other current assets	$	8
Property, plant, and equipment	5
Other intangible assets	48
Goodwill	56
Total assets acquired	117

Current liabilities	3
Deferred tax liabilities	3
Other liabilities	3
Total liabilities assumed	9
Net assets acquired	$	108

The Company accounted for the acquisitions above as business combinations using the acquisition method of accounting.

Acquisition-Related Items

During the three months ended July 29, 2016 and July 31, 2015, the Company recognized acquisition-related items expense of $52 million and $71 million, respectively, primarily due to integration-related costs incurred in connection with the Covidien acquisition.

Subsequent Acquisitions

On August 23, 2016, the Company's Cardiac and Vascular Group acquired HeartWare International, Inc. for total consideration of approximately $1.1 billion. The addition of HeartWare International, Inc.'s portfolio of heart failure products expands and strengthens the Company's heart failure product offerings and further complements its existing global cardiac rhythm and heart failure business.

On August 5, 2016, the Company's Minimally Invasive Therapies Group acquired Smith & Nephew's gynecology business for total consideration of approximately $350 million. The addition of Smith & Nephew's gynecology business expands and strengthens Medtronic's minimally invasive surgical offerings and further complements its existing global gynecology business.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Contingent Consideration

Certain of the Company’s business combinations involve the potential for the payment of future consideration upon the achievement of certain product development milestones and/or various other favorable operating conditions. Payment of the additional consideration is generally contingent on the acquired business reaching certain performance milestones, including attaining specified revenue levels or achieving product development targets. For business combinations subsequent to April 24, 2009, a liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value recognized as income or expense within acquisition-related items in the consolidated statements of income. The Company measures the liability on a recurring basis using Level 3 inputs.

The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected revenues are based on the Company’s most recent internal operational budgets and long-range strategic plans. Changes in projected revenues, probabilities of payment, discount rates, or projected payment dates may result in adjustments to the fair value measurement.

The recurring Level 3 fair value measurements of contingent consideration include the following significant unobservable inputs:



	Fair Value at
(in millions)	July 29, 2016	Valuation Technique	Unobservable Input	Range
			Discount rate	11% - 32.5%
Revenue-based payments	$194	Discounted cash flow	Probability of payment	30% - 100%
			Projected fiscal year of payment	2017 - 2025
			Discount rate	0.3% - 5.5%
Product development-based payments	$185	Discounted cash flow	Probability of payment	75% - 100%
			Projected fiscal year of payment	2017 - 2025

At July 29, 2016, the estimated maximum potential amount of undiscounted future contingent consideration payments that the Company is expected to make associated with all completed business combinations or purchases of intellectual property prior to April 24, 2009 was approximately $175 million. The Company estimates the milestones or other conditions associated with the contingent consideration will be reached in fiscal year 2017 and thereafter.

The fair value of contingent consideration associated with acquisitions subsequent to April 24, 2009, at July 29, 2016 and April 29, 2016, was $379 million and $377 million, respectively. At July 29, 2016, $321 million was reflected in other liabilities and $58 million was reflected in other accrued expenses in the consolidated balance sheets. At April 29, 2016, $311 million was reflected in other liabilities and $66 million was reflected in other accrued expenses in the consolidated balance sheets. The portion of the contingent consideration paid related to the acquisition date fair value is reported as financing activities in the consolidated statements of cash flows. Amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.

The following table provides a reconciliation of the beginning and ending balances of contingent consideration:



	Three months ended
(in millions)	July 29, 2016			July 31, 2015
Beginning Balance	$	377		$	264
Purchase price contingent consideration	21			26
Payments	(14		)	(3		)
Change in fair value	(5		)	4
Ending Balance	$	379		$	291

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

4. Restructuring Charges, Net

Cost Synergies Initiative

The cost synergies initiative is the Company's restructuring program primarily related to the integration of Covidien. This initiative is expected to contribute to the approximately $850 million in cost synergies expected to be achieved as a result of the integration of the Covidien acquisition through fiscal year 2018, including administrative office optimization, manufacturing and supply chain infrastructure, certain program cancellations, and certain general and administrative savings. Restructuring charges are expected to be incurred on a quarterly basis throughout fiscal year 2017 and in future fiscal years as cost synergy strategies are finalized.

A summary of the restructuring accrual, recorded within other accrued expenses and other liabilities in the consolidated balance sheets, and related activity is presented below:



(in millions)	Employee Termination Costs			Asset Write-downs			Other Costs			Total
April 29, 2016	$	213		$	—		$	37		$	250
Restructuring charges	77			14			20			111
Payments/write-downs	(68		)	(14		)	(16		)	(98		)
Reversal of excess accrual	(8		)	—			1			(7		)
July 29, 2016	$	214		$	—		$	42		$	256

As a result of certain employees identified for termination finding other positions within the Company, the Company recorded a $7 million reversal of excess restructuring reserves for the three months ended July 29, 2016.

As part of the cost synergies initiative, the Company recorded $14 million of asset write-downs for the three months ended July 29, 2016, which included $10 million related to inventory write-offs of discontinued product lines, and, therefore, was recognized within cost of products sold in the consolidated statements of income. For the three months ended July 29, 2016, asset write-downs included $4 million related to property, plant, and equipment impairments. The Company did not recognize any significant impairments during the three months ended July 31, 2015.

5. Financial Instruments

The Company holds investments consisting primarily of marketable debt and equity securities. The authoritative guidance is principally applied to financial assets and liabilities, such as marketable equity securities and debt and equity securities, that are classified and accounted for as trading and available-for-sale and are measured on a recurring basis. Further, we also hold cost or equity method investments which are measured at fair value on a nonrecurring basis.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at July 29, 2016:



	Valuation									Balance Sheet Classification
(in millions)	Cost		Unrealized Gains		Unrealized Losses			Fair Value		Investments		Other Assets
Available-for-sale securities:
Level 1:
U.S. government and agency securities	$	675	$	28	$	—		$	703	$	703	$	—
Marketable equity securities	85		45		(1		)	129		—		129
Total Level 1	760		73		(1		)	832		703		129
Level 2:
Corporate debt securities	4,113		123		(14		)	4,222		4,222		—
U.S. government and agency securities	914		3		—			917		917		—
Mortgage-backed securities	917		26		(16		)	927		927		—
Foreign government and agency securities	15		—		—			15		15		—
Other asset-backed securities	230		3		—			233		233		—
Debt funds	2,872		14		(246		)	2,640		2,640		—
Total Level 2	9,061		169		(276		)	8,954		8,954		—
Level 3:
Corporate debt securities	1		—		—			1		—		1
Auction rate securities	47		—		(3		)	44		—		44
Total Level 3	48		—		(3		)	45		—		45
Total available-for-sale securities	$	9,869	$	242	$	(280	)	$	9,831	$	9,657	$	174
Trading securities:
Level 1:
Exchange-traded funds	75		19		(1		)	93		93		—
Total Level 1	75		19		(1		)	93		93		—
Total trading securities	$	75	$	19	$	(1	)	$	93	$	93	$	—
Cost method, equity method, and other investments:
Level 3:
Cost method, equity method, and other investments	546		—		—			N/A		—		546
Total Level 3	546		—		—			N/A		—		546
Total cost method, equity method, and other investments	$	546	$	—	$	—		N/A		$	—	$	546
Total investments	$	10,490	$	261	$	(281	)	$	9,924	$	9,750	$	720

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at April 29, 2016:



	Valuation									Balance Sheet Classification
(in millions)	Cost		Unrealized Gains		Unrealized Losses			Fair Value		Investments		Other Assets
Available-for-sale securities:
Level 1:
U.S. government and agency securities	$	792	$	14	$	(1	)	$	805	$	805	$	—
Marketable equity securities	75		21		(11		)	85		—		85
Total Level 1	867		35		(12		)	890		805		85
Level 2:
Corporate debt securities	3,935		85		(24		)	3,996		3,996		—
U.S. government and agency securities	902		2		—			904		904		—
Mortgage-backed securities	1,016		17		(18		)	1,015		1,015		—
Other asset-backed securities	192		3		—			195		195		—
Debt funds	3,040		5		(281		)	2,764		2,764		—
Total Level 2	9,085		112		(323		)	8,874		8,874		—
Level 3:
Corporate debt securities	1		—		—			1		—		1
Auction rate securities	47		—		(3		)	44		—		44
Total Level 3	48		—		(3		)	45		—		45
Total available-for-sale securities	$	10,000	$	147	$	(338	)	$	9,809	$	9,679	$	130
Trading securities:
Level 1:
Exchange-traded funds	65		15		(1		)	79		79		—
Total Level 1	65		15		(1		)	79		79		—
Total trading securities	$	65	$	15	$	(1	)	$	79	$	79	$	—
Cost method, equity method, and other investments:
Level 3:
Cost method, equity method, and other investments	506		—		—			N/A		—		506
Total Level 3	506		—		—			N/A		—		506
Total cost method, equity method, and other investments	$	506	$	—	$	—		N/A		$	—	$	506
Total investments	$	10,571	$	162	$	(339	)	$	9,888	$	9,758	$	636

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Marketable Debt and Equity Securities

The following tables represents the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at July 29, 2016 and April 29, 2016:



	July 29, 2016
	Less than 12 months					More than 12 months
(in millions)	Fair Value		Unrealized Losses			Fair Value		Unrealized Losses
Corporate debt securities	$	494	$	(6	)	$	216	$	(8	)
Auction rate securities	—		—			44		(3		)
Mortgage-backed securities	208		(6		)	121		(10		)
Debt funds	851		—			1,789		(246		)
Marketable equity securities	$	4	$	(1	)	$	—	$	—
Total	$	1,557	$	(13	)	$	2,170	$	(267	)



	April 29, 2016
	Less than 12 months					More than 12 months
(in millions)	Fair Value		Unrealized Losses			Fair Value		Unrealized Losses
Corporate debt securities	$	756	$	(18	)	$	136	$	(6	)
Auction rate securities	—		—			44		(3		)
Mortgage-backed securities	196		(5		)	92		(5		)
U.S. government and agency securities	308		(4		)	67		(5		)
Debt funds	670		(26		)	1,601		(256		)
Marketable equity securities	45		(11		)	—		—
Total	$	1,975	$	(64	)	$	1,940	$	(275	)

The following table represents the range of the unobservable inputs utilized in the fair value measurement of the auction rate securities classified as Level 3 at July 29, 2016:



	Valuation Technique	Unobservable Input	Range (Weighted Average)
Auction rate securities	Discounted cash flow	Years to principal recovery	2 yrs. - 12 yrs. (3 yrs.)
Auction rate securities	Discounted cash flow	Illiquidity premium	6%

The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no transfers between Level 1, Level 2, or Level 3 during the three months ended July 29, 2016 or July 31, 2015. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The following tables provide a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that used significant unobservable inputs (Level 3):



(in millions)	Total Level 3 Investments			Corporate Debt Securities		Auction Rate Securities
April 29, 2016	$	45		$	1	$	44
Total unrealized losses included in other comprehensive income	—			—		—
July 29, 2016	$	45		$	1	$	44

(in millions)	Total Level 3 Investments			Corporate Debt Securities		Auction Rate Securities
April 24, 2015	$	106		$	1	$	105
Total unrealized losses included in other comprehensive income	(3		)	—		(3		)
July 31, 2015	$	103		$	1	$	102

Activity related to the Company’s investment portfolio is as follows:



	Three months ended
	July 29, 2016						July 31, 2015
(in millions)	Debt⁽¹⁾			Equity ⁽²⁾			Debt ⁽¹⁾			Equity ⁽²⁾
Proceeds from sales	$	1,098		$	6		$	1,237		$	29
Gross realized gains	7			4			5			12
Gross realized losses	(12		)	—			(5		)	—
Impairment losses recognized	—			(3		)	—			(23		)


(1)	Includes available-for-sale debt securities.


(2)	Includes marketable equity securities, cost method, equity method, exchange-traded funds, and other investments.

Credit losses represent the difference between the present value of cash flows expected to be collected on certain mortgage-backed securities and auction rate securities and the amortized cost of these securities. Based on the Company’s assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which the Company is invested, the Company believes it has recognized all necessary other-than-temporary impairments, as the Company does not have the intent to sell, nor is it more likely than not that the Company will be required to sell, before recovery of the amortized cost.

At July 29, 2016 and April 29, 2016, the credit loss portion of other-than temporary impairments on debt securities was not significant. The total reductions of available-for-sale debt securities sold during the three months ended July 29, 2016 and July 31, 2015 were not significant. The total other-than-temporary impairment losses on available-for-sale debt securities for the three months ended July 29, 2016 and July 31, 2015 were not significant.

The July 29, 2016 balance of available-for-sale debt securities, excluding debt funds which have no single maturity date, by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.



(in millions)	July 29, 2016
Due in one year or less	$	969
Due after one year through five years	3,188
Due after five years through ten years	2,845
Due after ten years	60
Total	$	7,062

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The Company holds investments in marketable equity securities, which are classified as other assets in the consolidated balance sheets. The aggregate carrying amount of these investments was $129 million and $85 million at July 29, 2016 and April 29, 2016, respectively. The Company did not recognize any significant impairment charges related to marketable equity securities during the three months ended July 29, 2016. During the three months ended July 31, 2015, the Company determined that the fair values of certain marketable equity securities were below the carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $20 million in impairment charges for the three months ended July 31, 2015, which were recognized within other expense, net in the consolidated statements of income.

Cost method, equity method, and other investments

The Company holds investments in equity and other securities that are accounted for using the cost or equity method, which are classified as other assets in the consolidated balance sheets. At July 29, 2016 and April 29, 2016, the aggregate carrying amount of equity and other securities without a quoted market price and accounted for using the cost or equity method was $546 million and $506 million, respectively. Cost and equity method investments are measured at fair value on a nonrecurring basis. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The values of cost and equity method investments are not assessed for impairment if there are no identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment.

During the three months ended July 29, 2016, the Company determined that the fair values of certain cost method investments were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $3 million in impairment charges during the three months ended July 29, 2016, which were recognized in other expense, net in the consolidated statements of income. The Company did not recognize any significant impairment charges related to cost method investments during the three months ended July 31, 2015. Cost method investments fall within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value, as the investments are in privately-held entities without quoted market prices. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the entities, including financial statements and market participant valuations from recent and proposed equity offerings.

6. Financing Arrangements

Commercial Paper

The Company maintains a commercial paper program that allows the Company to have a maximum of $3.5 billion in commercial paper outstanding. Commercial paper amounts outstanding at July 29, 2016 totaled $975 million. No amounts were outstanding at April 29, 2016. During the three months ended July 29, 2016, the weighted average original maturity of the commercial paper outstanding was approximately 21 days, and the weighted average interest rate was 0.73 percent. The issuance of commercial paper proportionately reduced the amount of credit available under the Company’s existing Credit Facility, as defined below.

Line of Credit

The Company has a $3.5 billion five year credit facility (Credit Facility) which provides back up funding for the commercial paper program described above. At July 29, 2016 and April 29, 2016, no amounts were outstanding.

Interest rates are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The agreement also contains customary covenants, all of which the Company remained in compliance with at July 29, 2016.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Long-Term Debt

Long-term debt consisted of the following:



(in millions, except interest rates)	Maturity by Fiscal Year	July 29, 2016			April 29, 2016
6.000 percent ten-year 2008 CIFSA senior notes	2018	$	1,150		$	1,150
1.500 percent three-year 2015 senior notes	2018	1,000			1,000
1.375 percent five-year 2013 senior notes	2018	1,000			1,000
5.600 percent ten-year 2009 senior notes	2019	400			400
4.450 percent ten-year 2010 senior notes	2020	766			766
2.500 percent five-year 2015 senior notes	2020	2,500			2,500
Floating rate five-year 2015 senior notes	2020	500			500
4.200 percent ten-year 2010 CIFSA senior notes	2021	600			600
4.125 percent ten-year 2011 senior notes	2021	500			500
3.125 percent ten-year 2012 senior notes	2022	675			675
3.150 percent seven-year 2015 senior notes	2022	2,500			2,500
3.200 percent ten-year 2012 CIFSA senior notes	2023	650			650
2.750 percent ten-year 2013 senior notes	2023	530			530
2.950 percent ten-year 2013 CIFSA senior notes	2024	310			310
3.625 percent ten-year 2014 senior notes	2024	850			850
3.500 percent ten-year 2015 senior notes	2025	4,000			4,000
4.375 percent twenty-year 2015 senior notes	2035	2,382			2,382
6.550 percent thirty-year 2008 CIFSA senior notes	2038	374			374
6.500 percent thirty-year 2009 senior notes	2039	300			300
5.550 percent thirty-year 2010 senior notes	2040	500			500
4.500 percent thirty-year 2012 senior notes	2042	400			400
4.000 percent thirty-year 2013 senior notes	2043	325			325
4.625 percent thirty-year 2014 senior notes	2044	650			650
4.625 percent thirty-year 2015 senior notes	2045	4,000			4,000
Three-year term loan	2018	3,000			3,000
Interest rate swaps (Note 7)	2018 - 2022	106			89
Capital lease obligations	2018 - 2025	25			26
Bank borrowings	2021	66			56
Debt premium	2018 - 2045	198			214
Deferred Financing Costs ⁽¹⁾	2018-2045	(133		)	(138		)
Total Long-Term Debt		$	30,124		$	30,109


(1)	We retrospectively adopted the guidance to simplify the presentation of deferred issuance costs in the quarter ending July 29, 2016. As a result deferred issuance costs have been reclassified from other assets to long-term debt. See Note 2 to the consolidated financial statements for additional information.

Senior Notes

The Company has outstanding unsecured senior obligations including those described as senior notes in the long-term debt table above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which the Senior Notes were issued contain customary covenants, all of which the Company remained in compliance with at July 29, 2016. The Company used the net proceeds from the sale of the Senior Notes primarily for working capital and general corporate uses, which includes the repayment of other indebtedness of the Company, and to fund the acquisition of Covidien in fiscal year 2015. For additional information regarding the terms of these agreements, refer to Note 7 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Financial Instruments Not Measured at Fair Value

At July 29, 2016, the total estimated fair value of the Company’s long-term debt, including the current portion, was $30.5 billion compared to a principal value of $27.4 billion; at April 29, 2016, the total estimated fair value was $29.8 billion compared to a principal value of $27.4 billion. The fair value was estimated using quoted market prices for the publicly registered senior notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and derivative/hedging activity.

7. Derivatives and Currency Exchange Risk Management

The Company uses operational and economic hedges, as well as currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. The primary currencies of the derivative instruments are the Euro and Japanese Yen. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding at July 29, 2016 and April 29, 2016 was $10.7 billion and $10.8 billion, respectively.

The information that follows explains the various types of derivatives and financial instruments used by the Company, reasons the Company uses such instruments, and the impact such instruments have on the Company’s consolidated balance sheets, statements of income, and statements of cash flows.

Freestanding Derivative Contracts

Freestanding derivative contracts are used to offset the Company’s exposure to the change in value of specific foreign currency denominated assets and liabilities and to offset variability of cash flows associated with forecasted transactions denominated in a foreign currency. The gross notional amount of these contracts, not designated as hedging instruments, outstanding at July 29, 2016 and April 29, 2016, was $4.9 billion and $5.0 billion, respectively.

The amounts and classification of the (losses) gains in the consolidated statements of income related to derivative instruments, not designated as hedging instruments, for the three months ended July 29, 2016 and July 31, 2015 were as follows:



(in millions)		Three months ended
Derivatives Not Designated as Hedging Instruments	Classification	July 29, 2016			July 31, 2015
Currency exchange rate contracts (losses) gains	Other expense, net	$	(3	)	$	20

Cash Flow Hedges

Currency Exchange Rate Risk

Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. No gains or losses relating to ineffectiveness of foreign currency cash flow hedges were recognized in earnings during the three months ended July 29, 2016 or July 31, 2015. No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness and no hedges were derecognized or discontinued during the three months ended July 29, 2016 or July 31, 2015. The gross notional amount of these contracts, designated as cash flow hedges, outstanding at July 29, 2016 and April 29, 2016, was $5.8 billion and $5.7 billion, respectively, and will mature within the subsequent three-year period.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The amount of gains (losses) and location of the gains (losses) in the consolidated statements of income and other comprehensive (loss) income (OCI) related to currency exchange rate contract derivative instruments designated as cash flow hedges for the three months ended July 29, 2016 and July 31, 2015 were as follows:



Three months ended July 29, 2016
	Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative			Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income
(in millions)
Derivatives in Cash Flow Hedging Relationships	Amount			Classification	Amount
Currency exchange rate contracts	$	121		Other expense, net	$	15
Three months ended July 31, 2015
	Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative			Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income
(in millions)
Derivatives in Cash Flow Hedging Relationships	Amount			Classification	Amount
Currency exchange rate contracts	$	(14	)	Other expense, net	$	95
				Cost of products sold	(21		)
Total	$	(14	)		$	74

Forecasted Debt Issuance Interest Rate Risk

Forward starting interest rate derivative instruments designated as cash flow hedges are designed to manage the exposure to interest rate volatility with regard to future issuances of fixed-rate debt. No gains or losses relating to ineffectiveness of forward starting interest rate derivative instruments were recognized in earnings during the three months ended July 29, 2016 or July 31, 2015. No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness during the three months ended July 29, 2016 or July 31, 2015. At July 29, 2016, the Company had $300 million of fixed pay, forward starting interest rate swaps with a weighted average fixed-rate of 3.10 percent in anticipation of planned debt issuances in fiscal year 2017.

For the three months ended July 29, 2016 and July 31, 2015, the reclassification of the effective portion of the net losses on forward starting interest rate derivative instruments from accumulated other comprehensive loss to interest expense, net was not significant.

The unrealized losses on outstanding forward starting interest rate swap derivative instruments at July 29, 2016 and April 29, 2016 were $71 million and $48 million, respectively. Unrealized losses on outstanding forward starting interest rate swap derivative instruments were recorded in other liabilities, with the offset recorded in accumulated other comprehensive loss in the consolidated balance sheets.

At July 29, 2016 and April 29, 2016, the Company had $36 million and $90 million, respectively, in after-tax net unrealized losses associated with cash flow hedging instruments recorded in accumulated other comprehensive loss. The Company expects that $53 million of after-tax net unrealized gains as of July 29, 2016 will be reclassified into the consolidated statements of income over the next 12 months.

Fair Value Hedges

Interest rate derivative instruments designated as fair value hedges are designed to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount.

At July 29, 2016 and April 29, 2016, the Company had interest rate swaps in gross notional amounts of $1.2 billion and $1.2 billion, respectively, designated as fair value hedges of underlying fixed-rate senior note obligations. For additional information regarding the terms of the Company’s interest rate swap agreements, refer to Note 8 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016.

At July 29, 2016, the market value of outstanding interest rate swap agreements was a net $106 million unrealized gain, and the market value of the hedged item was a net $106 million unrealized loss. The amounts which were recorded in other assets, other current assets, and other liabilities with the offsets recorded in long-term debt and current debt obligations in the consolidated

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

balance sheets. No significant hedge ineffectiveness was recorded as a result of these fair value hedges for the three months ended July 29, 2016 or July 31, 2015.

During the three months ended July 29, 2016 and July 31, 2015, the Company did not have any significant ineffective fair value hedging instruments. In addition, during the three months ended July 29, 2016 and July 31, 2015, the Company did not recognize any significant gains or losses on firm commitments that no longer qualify as fair value hedges.

Balance Sheet Presentation

The following tables summarize the balance sheet classification and fair value amounts of derivative instruments reported in the consolidated balance sheets at July 29, 2016 and April 29, 2016. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not and are further segregated by type of contract within those two categories.



July 29, 2016
	Asset Derivatives			Liability Derivatives
(in millions)	Balance Sheet Classification	Fair Value		Balance Sheet Classification	Fair Value
Derivatives designated as hedging instruments
Currency exchange rate contracts	Other current assets	191		Other accrued expenses	101
Interest rate contracts	Other assets	106		Other liabilities	71
Currency exchange rate contracts	Other assets	55		Other liabilities	55
Total derivatives designated as hedging instruments		$	352		$	227
Derivatives not designated as hedging instruments
Currency exchange rate contracts	Other current assets	$	26	Other accrued expenses	$	13
Cross currency interest rate contracts	Other assets	10		Other liabilities	10
Total derivatives not designated as hedging instruments		$	36		$	23

Total derivatives		$	388		$	250



April 29, 2016
	Asset Derivatives			Liability Derivatives
(in millions)	Balance Sheet Classification	Fair Value		Balance Sheet Classification	Fair Value
Derivatives designated as hedging instruments
Currency exchange rate contracts	Other current assets	$	123	Other accrued expenses	$	89
Interest rate contracts	Other assets	89		Other liabilities	48
Currency exchange rate contracts	Other assets	9		Other liabilities	54
Total derivatives designated as hedging instruments		$	221		$	191
Derivatives not designated as hedging instruments
Commodity derivatives	Other current assets	$	—	Other accrued expenses	$	1
Currency exchange rate contracts	Other current assets	13		Other accrued expenses	23
Cross currency interest rate contracts	Other assets	14		Other liabilities	4
Total derivatives not designated as hedging instruments		$	27		$	28

Total derivatives		$	248		$	219

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis at July 29, 2016 and April 29, 2016.



	July 29, 2016				April 29, 2016
(in millions)	Level 1		Level 2		Level 1		Level 2
Derivative assets	$	272	$	116	$	145	$	103
Derivative liabilities	169		81		166		53

The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.



July 29, 2016				Gross Amount Not Offset on the Balance Sheet
(in millions)	Gross Amount of Recognized Assets (Liabilities)			Financial Instruments			Collateral (Received) Posted		Net Amount
Derivative Assets
Currency exchange rate contracts	$	272		$	(189	)	$	—	$	83
Interest rate contracts	106			(20		)	—		86
Cross currency interest rate contracts	10			(5		)	—		5
	$	388		$	(214	)	$	—	$	174

Derivative Liabilities
Currency exchange rate contracts	$	(169	)	$	146		$	—	$	(23	)
Interest rate contracts	(71		)	63			—		(8		)
Cross currency interest rate contracts	(10		)	5			—		(5		)
	$	(250	)	$	214		$	—	$	(36	)
Total	$	138		$	—		$	—	$	138



April 29, 2016				Gross Amount Not Offset on the Balance Sheet
(in millions)	Gross Amount of Recognized Assets (Liabilities)			Financial Instruments			Collateral (Received) Posted			Net Amount
Derivative Assets
Currency exchange rate contracts	$	145		$	(98	)	$	(1	)	$	46
Interest rate contracts	89			(20		)	—			69
Cross currency interest rate contracts	14			—			—			14
	$	248		$	(118	)	$	(1	)	$	129

Derivative Liabilities
Currency exchange rate contracts	$	(166	)	$	85		$	26		$	(55	)
Interest rate contracts	(48		)	34			—			(14		)
Cross currency interest rate contracts	(4		)	—			—			(4		)
Commodity contracts	(1		)	—			—			(1		)
	$	(219	)	$	119		$	26		$	(74	)
Total	$	29		$	1		$	25		$	55

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

8. Inventories

Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for those items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors. Inventory balances were as follows:



(in millions)	July 29, 2016		April 29, 2016
Finished goods	$	2,346	$	2,242
Work in-process	497		499
Raw materials	737		732
Total	$	3,580	$	3,473

9. Goodwill and Other Intangible Assets, Net

Goodwill

The changes in the carrying amount of goodwill by reporting unit for the three months ended July 29, 2016 were as follows:



(in millions)	Cardiac and Vascular Group			Minimally Invasive Therapies Group			Restorative Therapies Group			Diabetes Group		Total
April 29, 2016	$	6,243		$	23,784		$	9,620		$	1,853	$	41,500
Goodwill as a result of acquisitions	27			(3		)	32			—		56
Currency adjustment, net	(11		)	(231		)	(5		)	—		(247		)
July 29, 2016	$	6,259		$	23,550		$	9,647		$	1,853	$	41,309

The Company assesses goodwill for impairment annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting unit level. The test for impairment of goodwill requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis. The Company did not recognize any goodwill impairment during the three months ended July 29, 2016 or July 31, 2015.

Intangible Assets

The gross carrying amount and accumulated amortization of intangible assets at July 29, 2016 and April 29, 2016 were as follows:



	July 29, 2016					April 29, 2016
(in millions)	Gross Carrying Amount		Accumulated Amortization			Gross Carrying Amount		Accumulated Amortization
Definite-lived:
Customer-related	$	18,614	$	(1,596	)	$	18,596	$	(1,331	)
Purchased technology and patents	11,537		(3,173		)	11,397		(2,976		)
Trademarks and tradenames	804		(425		)	854		(403		)
Other	72		(34		)	72		(31		)
Total	$	31,027	$	(5,228	)	$	30,919	$	(4,741	)
Indefinite-lived:
IPR&D	$	638				$	721

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The Company assesses definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company did not recognize any intangible asset impairments during the three months ended July 29, 2016 or July 31, 2015.

The Company assesses indefinite-lived intangibles for impairment annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The indefinite-lived intangibles impairment test requires the Company to perform an assessment involving several estimates about fair value. The Company calculates the excess of indefinite-lived intangibles asset fair values over their carrying values utilizing a discounted future cash flow analysis. During the three months ended July 29, 2016 and July 31, 2015, the Company did not recognize any indefinite-lived intangibles impairments. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances or other failures to achieve a commercially viable product, and as a result, may recognize impairment losses in the future.

Amortization Expense

Intangible asset amortization expense for the three months ended July 29, 2016 and July 31, 2015, was $487 million and $481 million, respectively.

Estimated aggregate amortization expense by fiscal year based on the current carrying value of definite-lived intangible assets at July 29, 2016, excluding any possible future amortization associated with acquired IPR&D, which has not met technological feasibility, is as follows:



(in millions)	Amortization Expense
Remaining 2017	$	1,449
2018	1,905
2019	1,811
2020	1,763
2021	1,746
2022	1,705

10. Income Taxes

During the first quarter of fiscal year 2017, the Company recognized a $31 million net benefit from certain tax adjustments. This net benefit was recognized within provision for income taxes in the consolidated statements of income. A $431 million tax benefit was recognized as the result of the resolution of Covidien’s previously disclosed Tyco International plc intercompany debt issues with the U.S. Tax Court and the Appeals Division of the U.S. Internal Revenue Service (IRS). This benefit was partially offset by a $371 million charge associated with the expected resolution with the IRS for the Ardian, CoreValve, Inc. and Ablation Frontiers, Inc. acquisition-related issues and the allocation of income between Medtronic, Inc. and its wholly owned subsidiary operating in Puerto Rico for certain businesses. This resolution does not include the businesses that are the subject of the Medtronic, Inc. U.S. Tax Court case for fiscal years 2005 and 2006. In addition, a $29 million charge was recognized in connection with the redemption of an intercompany minority interest.

The Company’s effective tax rate for the three months ended July 29, 2016 was 6.0 percent compared to 12.8 percent for the three months ended July 31, 2015. The decrease in the effective tax rate for the three months ended July 29, 2016 was primarily due to certain tax adjustments recognized during the quarter, finalization of certain tax returns, and changes to uncertain tax position reserves.

At July 29, 2016, the Company's gross unrecognized tax benefits were $1.9 billion, compared to $2.7 billion at April 29, 2016. In addition, the Company accrued gross interest and penalties of $261 million at July 29, 2016. If all of the Company’s unrecognized tax benefits were recognized, approximately $1.8 billion would impact the Company’s effective tax rate. The Company has recorded all of the gross unrecognized tax benefits as a non-current liability within accrued income taxes in the consolidated balance sheets. The Company will continue to recognize interest and penalties related to income tax matters within provision for income taxes in the consolidated statements of income and record the liability within accrued income taxes in the consolidated balance sheets.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

See Note 15 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

11. Earnings Per Share

Earnings per share is calculated using the two-class method, as the Company's A Preferred Shares are considered participating securities. Accordingly, earnings are allocated to both ordinary shares and participating securities in determining earnings per ordinary share. Due to the limited number of A Preferred Shares outstanding, this allocation had no effect on ordinary earnings per share; therefore, it is not presented below. Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted average number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock options and other stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.

The table below sets forth the computation of basic and diluted earnings per share:



	Three months ended
(in millions, except per share data)	July 29, 2016		July 31, 2015
Numerator:
Net income attributable to ordinary shareholders	$	929	$	820
Denominator:
Basic – weighted average shares outstanding	1,392.2		1,418.1
Effect of dilutive securities:
Employee stock options	10.5		13.2
Employee restricted stock units	3.9		5.0
Other	0.5		0.1
Diluted – weighted average shares outstanding	1,407.1		1,436.4

Basic earnings per share	$	0.67	$	0.58
Diluted earnings per share	$	0.66	$	0.57

The calculation of weighted average diluted shares outstanding excludes options to purchase approximately 4 million and 1 million ordinary shares for the three months ended July 29, 2016 and July 31, 2015, respectively, because their effect would be anti-dilutive on the Company’s earnings per share. Additionally, the calculation of weighted average diluted shares outstanding excludes approximately 5 million shares and approximately 20 million shares for the three months ended July 29, 2016 and July 31, 2015 respectively, because the performance criteria had not yet been met. The calculation of weighted average diluted shares outstanding excludes approximately 1 million restricted stock units for each of the three months ended July 29, 2016 and July 31, 2015, because the performance criteria had not yet been met.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

12. Stock-Based Compensation

The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock awards, and employee stock purchase plan shares recognized for the three months ended July 29, 2016 and July 31, 2015:



	Three months ended
(in millions)	July 29, 2016			July 31, 2015
Stock options	$	38		$	57
Restricted stock awards	34			34
Employee stock purchase plan shares	7			5
Total stock-based compensation expense	$	79		$	96

Cost of products sold	$	11		$	12
Research and development expense	9			8
Selling, general, and administrative expense	51			49
Restructuring charges, net	1			8
Acquisition-related items	7			19
Total stock-based compensation expense	$	79		$	96
Income tax benefits	(21		)	(29		)
Total stock-based compensation expense, net of tax	$	58		$	67

13. Retirement Benefit Plans

The Company sponsors various retirement benefit plans, including defined benefit pension plans (pension benefits), post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three months ended July 29, 2016 and July 31, 2015:



	U.S. Pension Benefits						Non-U.S. Pension Benefits
	Three months ended						Three months ended
(in millions)	July 29, 2016			July 31, 2015			July 29, 2016			July 31, 2015
Service cost	$	29		$	30		$	19		$	22
Interest cost	27			31			6			9
Expected return on plan assets	(47		)	(45		)	(12		)	(13		)
Amortization of net actuarial loss	23			24			4			6
Net periodic benefit cost	$	32		$	40		$	17		$	24

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

14. Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure

Changes in AOCI by component are as follows:



(in millions)	Unrealized Gain (Loss) on Available-for-Sale Securities ⁽¹⁾			Cumulative Translation Adjustments ⁽²⁾			Net Change in Retirement Obligations⁽³⁾			Unrealized Gain (Loss) on Derivatives ⁽⁴⁾			Total Accumulated Other Comprehensive (Loss) Income
April 29, 2016, net of tax	$	(107	)	$	(474	)	$	(1,197	)	$	(90	)	$	(1,868	)
Other comprehensive income (loss) before reclassifications, before tax	168			(350		)	—			98			(84		)
Tax expense	(52		)	—			—			(36		)	(88		)
Other comprehensive income (loss) before reclassifications, net of tax	116			(350		)	—			62			(172		)
Reclassifications, before tax	(1		)	—			27			(14		)	12
Tax (expense) benefit	—			—			(2		)	6			4
Reclassifications, net of tax	(1		)	—			25			(8		)	16
Other comprehensive income (loss), net of tax	115			(350		)	25			54			(156		)
July 29, 2016, net of tax	$	8		$	(824	)	$	(1,172	)	$	(36	)	$	(2,024	)

(in millions)	Unrealized Gain (Loss) on Available-for-Sale Securities ⁽¹⁾			Cumulative Translation Adjustments ⁽²⁾			Net Change in Retirement Obligations⁽³⁾			Unrealized Gain (Loss) on Derivatives⁽⁴⁾			Total Accumulated Other Comprehensive (Loss) Income
April 24, 2015, net of tax	$	14		$	(277	)	$	(1,131	)	$	210		$	(1,184	)
Other comprehensive (loss) income before reclassifications, before tax	(193		)	(26		)	(7		)	14			(212		)
Tax benefit (expense)	70			—			—			(6		)	64
Other comprehensive (loss) income before reclassifications, net of tax	(123		)	(26		)	(7		)	8			(148		)
Reclassifications, before tax	(12		)	—			30			(62		)	(44		)
Tax benefit (expense)	4			—			(10		)	26			20
Reclassifications, net of tax	(8		)	—			20			(36		)	(24		)
Other comprehensive (loss) income, net of tax	(131		)	(26		)	13			(28		)	(172		)
July 31, 2015, net of tax	$	(117	)	$	(303	)	$	(1,118	)	$	182		$	(1,356	)


(1)	Represents net realized gains (losses) on sales of available-for-sale securities that were reclassified from AOCI to other expense, net (see Note 5).


(2)	Taxes are not provided on cumulative translation adjustments as substantially all translation adjustments relate to earnings that are intended to be indefinitely reinvested outside the U.S.


(3)	Includes net amortization of prior service costs and actuarial losses included in net periodic benefit cost (see Note 13).


(4)	Relates to currency cash flow hedges that were reclassified from AOCI to other expense, net or cost of products sold and forward starting interest rate derivative instruments that were reclassified from AOCI to interest expense, net (see Note 7).

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

The supplemental equity schedule below presents changes in the Company's noncontrolling interests and total shareholders' equity for the three months ended July 29, 2016.



(in millions)	Total Shareholders' Equity			Noncontrolling Interests		Total Equity
April 29, 2016	$	52,063		$	—	$	52,063
Net income	929			—		929
Other comprehensive loss	(156		)	—		(156		)
Dividends to shareholders	(599		)	—		(599		)
Issuance of shares under stock purchase and award plans	214			—		214
Repurchase of ordinary shares	(1,763		)	—		(1,763		)
Tax benefit from exercise of stock-based awards	57			—		57
Stock-based compensation	79			—		79
Additions of noncontrolling ownership interests	—			68		68
July 29, 2016	$	50,824		$	68	$	50,892

15. Commitments and Contingencies

The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property disputes, shareholder related matters, environmental proceedings, income tax disputes, and governmental proceedings and investigations in the United States and around the world, including those described below. With respect to governmental proceedings and investigations, our standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures or result in lost revenues. The Company records a liability in the consolidated financial statements for loss contingencies related to legal actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company recognized an additional expense of $82 million in the first quarter of fiscal year 2017 related to probable and estimable damages. At July 29, 2016 and April 29, 2016, accrued certain litigation charges were approximately $1.1 billion and $1.0 billion, respectively. The ultimate cost to the Company with respect to accrued certain litigation charges could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, or cash flows. The Company includes accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets.

In addition to litigation contingencies, the Company also has certain income tax and guarantee obligations that may potentially result in future costs. While it is not possible to predict the outcome for most of the matters discussed below, the Company believes it is possible that costs associated with them could have a material adverse impact on the Company’s consolidated earnings, financial position, or cash flows.

Product Liability Matters

Sprint Fidelis

In 2007, a putative class action was filed in the Ontario Superior Court of Justice in Canada seeking damages for personal injuries allegedly related to the Company's Sprint Fidelis family of defibrillation leads. On October 20, 2009, the court certified a class proceeding but denied class certification on plaintiffs' claim for punitive damages. Pretrial proceedings are underway. The Company has not recognized an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

INFUSE Litigation

The Company estimates law firms representing approximately 6,000 claimants have asserted or intend to assert personal injury claims against Medtronic in the U.S. state and federal courts involving the INFUSE bone graft product. As of September 1, 2016, the Company has reached agreements to settle approximately 4,300 of these claims, and certain of the remaining claims are expected to proceed to trial beginning in fiscal year 2017. The Company's accrued expenses for this matter are included within accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets as discussed above.

Other INFUSE Litigation

On June 5, 2014, Humana, Inc. filed a lawsuit for unspecified monetary damages in the U.S. District Court for the Western District of Tennessee, alleging that Medtronic, Inc. violated federal racketeering (RICO) law and various state laws, by conspiring with physicians to promote unapproved uses of INFUSE. In September of 2015 the Court granted Medtronic’s motion to dismiss the primary allegations, including the RICO claims, in Humana’s complaint. In April of 2016 the Court denied Humana's motion to file an amended complaint. The Company has not recognized an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter.

Pelvic Mesh Litigation

The Company, through the acquisition of Covidien, is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In July 2015, the Company and Bard agreed that Bard would pay the Company $121 million towards the settlement of 11,000 of these claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 15,800 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of September 1, 2016, the Company has reached agreements to settle approximately 6,200 of these claims. The Company's accrued expenses for this matter are included within accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets as discussed above.

Patent Litigation

Ethicon

On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015. Following appeal, the case was remanded back to the District Court with respect to one patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. In addition to claims of non-infringement, the Company asserts affirmative defenses of invalidity for each of the patents-in-suit. The case is currently in the early stages of fact discovery. The Company has not recognized an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter.

Shareholder Related Matters

INFUSE

On March 12, 2012, Charlotte Kokocinski (Kokocinski) filed a shareholder derivative action against both Medtronic, Inc. and certain of its current and former officers and directors in the U.S. District Court for the District of Minnesota, setting forth certain allegations, including a claim that defendants violated various purported duties in connection with the INFUSE bone graft product and otherwise. On March 25, 2013, the Court dismissed the case without prejudice, and Kokocinski subsequently filed an amended complaint. On March 30, 2015, the Court granted defendants’ motion to dismiss the amended complaint, dismissing the case with prejudice. Kokocinski sought reconsideration of that decision, and, on September 30, 2015, the Court denied Kokocinski’s request for reconsideration. Kokocinski has appealed the Court’s decision to the U.S. Court of Appeals for the Eighth Circuit.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

West Virginia Pipe Trades and Phil Pace, on June 27, 2013 and July 3, 2013, respectively, filed putative class action complaints against Medtronic, Inc. and certain of its officers in the U.S. District Court for the District of Minnesota, alleging that the defendants made false and misleading public statements regarding the INFUSE Bone Graft product during the period of December 8, 2010 through August 3, 2011. The matters were consolidated in September, 2013, and in the consolidated complaint plaintiffs alleged a class period of September 28, 2010 through August 3, 2011. On September 30, 2015, the Court granted defendants’ motion for summary judgment in the consolidated matters. Plaintiffs have appealed the dismissal to the U.S. Court of Appeals for the Eighth Circuit.

COVIDIEN ACQUISITION

On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the Merenstein and Steiner matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On December 30, 2014, a hearing was held on plaintiffs’ motion for preliminary injunction and on defendants’ motion to dismiss. On January 2, 2015, the District Court denied the plaintiffs’ motion for preliminary injunction and on January 5, 2015 issued its opinion. On March 20, 2015, the District Court issued its order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, reversed in part, and remanded the case to the District Court for further proceedings. In February of 2016, the Company petitioned the Minnesota Supreme Court to review the decision of the Minnesota State Court of Appeals, and on April 19, 2016 the Minnesota Supreme Court granted the Company’s petition on the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. A decision from the Minnesota Supreme Court is expected in calendar year 2017.

The Company has not recognized an expense related to damages in connection with the shareholder related matters, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters.

Environmental Proceedings

The Company, through the acquisition of Covidien, is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.

The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008. The compliance order included a directive to remove a significant volume of soils at the site. On December 19, 2008, Covidien filed an appeal with the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order. A hearing before the Maine Board began on January 25, 2010 and concluded on February 4, 2010. On August 19, 2010, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills.

On April 3, 2014, the Maine Supreme Judicial Court affirmed the Maine Board’s compliance order. The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order.

The Company has also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring Covidien to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary.

On July 29, 2002, following a March 2002 trial, the District Court entered an opinion and order which held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that Covidien was liable for the cost of performing a study of the river and bay. The District Court subsequently appointed an independent study panel to oversee the study

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

and ordered Covidien to pay costs associated with the study. A report issued by the study panel contains recommendations for a variety of potential remedial options which could be implemented individually or in a variety of combinations, and included preliminary cost estimates for a variety of potential remedial options, which the report describes as “very rough estimates of cost,” ranging from $25 million to $235 million. The report indicates that these costs are subject to uncertainties, and that before any remedial option is implemented, further engineering studies and engineering design work are necessary to determine the feasibility of the proposed remedial options. In June of 2014, a trial was held to determine if remediation was necessary and feasible, and on September 2, 2015, the District Court issued an order concluding that further engineering study and engineering design work is appropriate to determine the nature and extent of remediation in the Penobscot River and Bay. In January of 2016, the Court appointed an engineering firm to conduct the next phase of the study. The study is targeted for completion late calendar year 2017.

The Company's accrued expenses for environmental proceedings are included within accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets as discussed above.

Government Matters

Medtronic has received subpoenas or document requests from the Attorneys General in Massachusetts, California, Oregon, Illinois, and Washington seeking information regarding sales, marketing, clinical, and other information relating to the INFUSE bone graft product. The Company has not recognized an expense related to damages in connection with these matters, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters.

On May 2, 2011, the U.S. Attorney’s Office for the District of Massachusetts issued a subpoena to ev3, a subsidiary of the Company, requesting production of documents relating to sales and marketing and other issues in connection with several neurovascular products. The matters under investigation relate to activities prior to Covidien's acquisition of ev3 in 2010. ev3 complied as required with the subpoena and cooperated with the investigation. In the third quarter of fiscal year 2016, the Company accrued expenses in connection with this matter, which are included within accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets as discussed above.

On September 2, 2014, the U.S. Department of Health and Human Services, Office of Inspector General and the U.S. Attorney’s Office for the Northern District of California, issued a subpoena requesting production of documents relating to sales and marketing practices associated with certain of ev3’s peripheral vascular products. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter.

Income Taxes

In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. On December 23, 2010, the IRS issued a statutory notice of deficiency with respect to the remaining issues. Medtronic, Inc. filed a petition with the U.S. Tax Court on March 21, 2011 objecting to the deficiency. During October and November 2012, Medtronic, Inc. reached resolution with the IRS on various matters, including the deductibility of a settlement payment. Medtronic, Inc. and the IRS agreed to hold one issue, the calculation of amounts eligible for the one-time repatriation holiday, because such specific issue was being addressed by other taxpayers in litigation with the IRS. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court proceeding with respect to this issue began on February 3, 2015 and ended on March 12, 2015. On June 9, 2016, the U.S. Tax court issued its opinion with respect to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. An Appeal of the U.S. Tax Court Opinion must be filed within 90 days of the final decision by the Tax Court. The final decision will not occur until all issues related to the fiscal years are resolved. As one item remains open, the calculation of amounts eligible for the one-time repatriation holiday, a final decision is not expected until later this fiscal year.

In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. During the first quarter of fiscal year 2016, the Company finalized its agreement with the IRS on the proposed adjustments associated with the tax effects of the Company's acquisition of Kyphon Inc. (Kyphon). The settlement was consistent with the certain tax adjustment recorded during the fourth quarter of fiscal year 2015. During the first quarter of fiscal year 2017, an expected settlement was reached with the IRS for all outstanding issues for fiscal years 2007 and 2008 except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the tax effects of its acquisition structures for Ardian, CoreValve, Inc., and Ablation Frontiers, Inc. During the first quarter of fiscal year 2017, an expected settlement was reached with the IRS for all outstanding issues for fiscal years 2009, 2010, and 2011 except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. The IRS continues to audit Medtronic, Inc.'s U.S. federal income tax returns for the fiscal years 2012 through 2014.

Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for the 2008 and 2009 tax years. The IRS continues to audit Covidien’s U.S. federal income tax returns for the years 2010 through 2012. Open periods for examination also include certain periods during which Covidien was a subsidiary of Tyco International plc (Tyco International). The resolution of these matters is subject to the conditions set forth in the Tyco tax sharing agreement (Tax Sharing Agreement). Tyco International has the right to administer, control and settle all U.S. income tax audits for periods prior to the 2007 separation.

The IRS concluded its field examination of certain of Tyco International’s U.S. federal income tax returns for the years 1997 through 2000 and proposed tax adjustments, several of which also affect Covidien’s income tax returns for certain years after 2000. Tyco International appealed certain of the tax adjustments proposed by the IRS and had resolved all but one of the matters associated with the proposed tax adjustments. The IRS asserted that substantially all of Tyco International’s intercompany debt originating during the years 1997 through 2000 should not be treated as debt for U.S. federal income tax purposes, and disallowed interest deductions related to the intercompany debt and certain tax attribute adjustments recognized on Tyco International’s U.S. income tax returns. The Company disagreed with the IRS’s proposed adjustments and, on July 22, 2013, Tyco International filed a petition with the U.S. Tax Court contesting the IRS assessment. On January 15, 2016, Tyco International, as audit managing party under the Tax Sharing Agreement, entered into Stipulations of Settled Issues with the IRS intended to resolve all Federal tax disputes related to this intercompany debt issue for the Tax Sharing Participants for the 1997 - 2000 audit cycle before the U.S. Tax Court. The Stipulations of Settled Issues were contingent upon the IRS Appeals Division applying the same settlement terms to all intercompany debt issues on appeal for subsequent audit cycles (2001 - 2007). On May 17, 2016 the IRS Office of Appeals issued fully executed Forms 870-AD that effectively settled the matters on appeal on the same terms as those set forth in the Stipulations of Settled Issues, and on May 31, 2016 the U.S. Tax Court entered decisions consistent with the Stipulations of Settled Issues. As a result, all aspects of this controversy that were before the U.S. Tax Court and Appeals Division of the IRS have been finally resolved for audit cycles from 1997-2007.

See Note 10 for additional discussion of income taxes.

Guarantees

As a result of the acquisition of Covidien, the Company has guarantee commitments and indemnifications with Tyco International, TE Connectivity Ltd. (TE Connectivity), and Mallinckrodt plc (Mallinckrodt) which relate to certain contingent tax liabilities.

On June 29, 2007, Covidien entered into the Tax Sharing Agreement, under which Covidien shares responsibility for certain of its, Tyco International’s, and TE Connectivity’s income tax liabilities for periods prior to Covidien’s 2007 separation from Tyco International (2007 separation). Covidien, Tyco International, and TE Connectivity share 42 percent, 27 percent, and 31 percent, respectively, of U.S. income tax liabilities that arise from adjustments made by tax authorities to Covidien's, Tyco International’s, and TE Connectivity’s U.S. income tax returns, certain income tax liabilities arising from adjustments made by tax authorities to intercompany transactions or similar adjustments, and certain taxes attributable to internal transactions undertaken in anticipation of the 2007 separation. If Tyco International and TE Connectivity default on their obligations to the Company under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties.

In connection with the 2007 separation, all tax liabilities associated with Covidien business became Covidien’s tax liabilities. Following Covidien’s spin-off of its Pharmaceuticals business to Covidien shareholders through a distribution of all the outstanding ordinary shares of Mallinkrodt (2013 separation), Mallinckrodt became the primary obligor to the taxing authorities for the tax liabilities attributable to its subsidiaries, a significant portion of which relate to periods prior to the 2007 separation. However, Covidien remains the sole party subject to the Tax Sharing Agreement. Accordingly, Mallinckrodt does not share in the Company’s liability to Tyco International and TE Connectivity, nor in the receivable that the Company has from Tyco International, and TE Connectivity.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

If any party to the Tax Sharing Agreement were to default in its obligation to another party to pay its share of the distribution taxes that arise as a result of no party’s fault, each non-defaulting party would be required to pay, equally with any other non-defaulting party, the amounts in default. In addition, if another party to the Tax Sharing Agreement that is responsible for all or a portion of an income tax liability were to default in its payment of such liability to a taxing authority, the Company could be legally liable under applicable tax law for such liabilities and be required to make additional tax payments. Accordingly, under certain circumstances, the Company may be obligated to pay amounts in excess of the Company’s agreed upon share of Covidien's, Tyco International’s and TE Connectivity’s tax liabilities.

The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tax Sharing Agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, primarily related to certain pre-2007 separation tax liabilities and tax years open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien, and/or TE Connectivity legal entities for periods prior to the 2007 separation. The resolutions with the U.S. Tax Court and IRS Appeals for fiscal years 1997 through 2007 were finalized during May 2016. However, the Tax Sharing Agreement remains in place with respect to income tax liabilities that are not the subject of such resolution.

In conjunction with the 2013 separation, Mallinckrodt assumed the tax liabilities that are attributable to its subsidiaries, and Covidien indemnified Mallinckrodt to the extent that such tax liabilities arising from periods prior to 2013 exceed $200 million, net of certain tax benefits realized. In addition, in connection with the 2013 separation, Covidien entered into certain other guarantee commitments and indemnifications with Mallinckrodt.

See Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016 for additional information.

Except as described above in this note or for certain income tax related matters, the Company has not recognized an expense related to losses in connection with these matters because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters.

In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of them to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising out of the Company or its affiliates’ products or the negligence of any of their personnel or claims alleging that any of their products infringe third-party patents or other intellectual property. The Company’s maximum exposure under these indemnification provisions cannot be estimated, and the Company has not accrued any liabilities within the consolidated financial statements. Historically, the Company has not experienced significant losses on these types of indemnifications.

16. Segment and Geographic Information

Segment information

The Company’s management evaluates performance and allocates resources based on profit and loss from operations before income taxes and interest expense, net, not including corporate determined charges, as presented in the table below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016.

In the first quarter of fiscal year 2017, the Company realigned the divisions within the Restorative Therapies Group. The Restorative Therapies Group consists of the following divisions: Spine, Brain Therapies, Pain Therapies, and Specialty Therapies.

Net sales of the Company’s reportable segments include end-customer revenues from the sale of products each reportable segment develops and manufactures or distributes. Net sales and income from operations before income taxes by reportable segment are as follows:



	Three months ended
(in millions)	July 29, 2016		July 31, 2015
Cardiac and Vascular Group	$	2,518	$	2,567
Minimally Invasive Therapies Group	2,424		2,456
Restorative Therapies Group	1,772		1,806
Diabetes Group	452		445
Total net sales	$	7,166	$	7,274

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)



	Three months ended
(in millions)	July 29, 2016			July 31, 2015
Cardiac and Vascular Group	$	656		$	817
Minimally Invasive Therapies Group	283			334
Restorative Therapies Group	507			481
Diabetes Group	112			117
Total reportable segments’ income from operations before income taxes	1,558			1,749
Impact of inventory step-up	—			(226		)
Restructuring charges, net	(104		)	(67		)
Certain litigation charges	(82		)	—
Acquisition-related items	(52		)	(71		)
Interest expense, net	(179		)	(191		)
Corporate	(153		)	(254		)
Total income from operations before income taxes	$	988		$	940

Geographic information

Net sales to external customers by geography are as follows:



	Three months ended
(in millions)	July 29, 2016		July 31, 2015
Americas ⁽¹⁾	$	4,297	$	4,445
EMEA ⁽²⁾	1,650		1,669
Asia-Pacific	822		770
Greater China	397		390
Total net sales	$	7,166	$	7,274

(1) The U.S., which is included in the Americas, had net sales to external customers of $4.0 billion for the three months ended July 29, 2016, and of $4.1 billion for the three months ended July 31, 2015.

(2) EMEA consists of the following regions: Europe, Middle East, and Africa. Sales to Ireland were insignificant during all periods presented.

17. Guarantor Financial Information

Medtronic plc (Parent Company Guarantor) and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a Subsidiary Guarantor, each have provided full and unconditional guarantees of the obligations of Medtronic, Inc. under the Senior Notes (Medtronic Senior Notes) and full and unconditional guarantees of the obligations of Covidien International Finance S.A. (CIFSA) under the Senior Notes (CIFSA Senior Notes). The guarantees of the CIFSA Senior Notes are in addition to the guarantees of the CIFSA Senior Notes by Covidien Ltd. and Covidien Group Holdings Ltd. The guarantees provided by the Parent Company Guarantor and Subsidiary Guarantor(s) are joint and several. A summary of the guarantees is as follows:

Guarantees of Medtronic Senior Notes


•	Parent Company Guarantor - Medtronic plc


•	Subsidiary Issuer - Medtronic, Inc.


•	Subsidiary Guarantor - Medtronic Luxco

Guarantees of CIFSA Senior Notes


•	Parent Company Guarantor - Medtronic plc


•	Subsidiary Issuer - CIFSA


•	Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd.

The following presents the Company’s Consolidating Statements of Comprehensive Income for the three months ended July 29, 2016 and July 31, 2015, Condensed Consolidating Balance Sheets at July 29, 2016 and April 29, 2016, and Condensed Consolidating Statements of Cash Flows for the three months ended July 29, 2016 and July 31, 2015. Condensed consolidating financial information for the Parent Company Guarantor, Subsidiary Issuer, and Subsidiary Guarantor(s), on a stand-alone basis, is presented using the equity method of accounting.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

During the first quarter of fiscal year 2017, the Company undertook certain steps to reorganize ownership of various subsidiaries. The transactions were entirely among subsidiaries under the common control of Medtronic. This reorganization has been reflected as of the beginning of the earliest period presented.

The Company made revisions to its condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes and CIFSA Senior Notes as previously presented in Note 19 in the Company’s Annual Report on Form 10-K for the year ended April 29, 2016 primarily due to an income statement error recognized in the second quarter of fiscal year 2016, resulting in an incorrect presentation of the investment in subsidiaries balances. In the condensed consolidating balance sheet of the guarantees of the Medtronic Senior Notes the $5.1 billion revision increased the line items Investment in Subsidiaries and Shareholders' Equity in the Subsidiary Issuer (Medtronic, Inc.) column. In the condensed consolidating balance sheet of the guarantees of the CIFSA Senior Notes the $5.1 billion revision decreased the line items Investment in Subsidiaries and Shareholders' Equity in the Subsidiary Issuer (CIFSA) column.

Additionally, the Company revised the classification of a previously reported $20.5 billion intercompany payable balance in the Parent Guarantor (Medtronic plc) column. The $20.5 billion revision decreased the Investment in Subsidiaries and Intercompany Payable balances in the Parent Guarantor (Medtronic plc) column and decreased the Investment in Subsidiaries and Shareholders’ Equity balances in the Subsidiary Guarantor column in both the condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes and CIFSA Senior Notes, decreased the Intercompany Receivable and Shareholders’ Equity balances in the Subsidiary Issuer (Medtronic, Inc.) column in the condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes, and decreased the Intercompany Receivable and Shareholders’ Equity balances in the Subsidiary Non-Guarantors column in the condensed consolidating balance sheets of the guarantees of the CIFSA Notes as previously presented in Note 19 in the Company’s Annual Report on Form 10-K for the year ended April 29, 2016. There is no impact to the consolidated financial statements of Medtronic plc as previously filed in the 2016 Annual Report on Form 10-K or Quarterly Reports on Form 10-Q.

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Consolidating Statement of Comprehensive Income

Three Months Ended July 29, 2016

Medtronic Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantor			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Net sales	$	—		$	348		$	—		$	7,166		$	(348	)	$	7,166

Costs and expenses:
Cost of products sold	—			250			—			2,365			(354		)	2,261
Research and development expense	—			163			—			393			—			556
Selling, general, and administrative expense	3			280			—			2,145			—			2,428
Restructuring charges, net	—			16			—			78			—			94
Certain litigation charges	—			—			—			82			—			82
Acquisition-related items	—			23			—			29			—			52
Amortization of intangible assets	—			3			—			484			—			487
Other (income) expense, net	11			(640		)	—			668			—			39
Operating profit (loss)	(14		)	253			—			922			6			1,167

Interest income	—			(60		)	(156		)	(282		)	405			(93		)
Interest expense	16			408			1			252			(405		)	272
Interest expense (income), net	16			348			(155		)	(30		)	—			179
Equity in net (income) loss of subsidiaries	(957		)	(1,246		)	(802		)	—			3,005			—
Income from operations before income taxes	927			1,151			957			952			(2,999		)	988
Provision (benefit) for income taxes	(2		)	22			—			39			—			59
Net income	929			1,129			957			913			(2,999		)	929
Other comprehensive income (loss), net of tax	(156		)	95			(156		)	(172		)	233			(156		)
Total comprehensive income	$	773		$	1,224		$	801		$	741		$	(2,766	)	$	773

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Consolidating Statement of Comprehensive Income

Three Months Ended July 31, 2015

Medtronic Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantor			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Net sales	$	—		$	373		$	—		$	7,274		$	(373	)	$	7,274

Costs and expenses:
Cost of products sold	—			256			—			2,546			(346		)	2,456
Research and development expense	—			162			—			396			—			558
Selling, general, and administrative expense	2			249			—			2,198			—			2,449
Restructuring charges, net	—			2			—			65			—			67
Acquisition-related items	—			35			—			36			—			71
Amortization of intangible assets	—			3			—			478			—			481
Other (income) expense, net	73			(388		)	—			376			—			61
Operating profit (loss)	(75		)	54			—			1,179			(27		)	1,131

Interest income	—			(64		)	(183		)	(113		)	245			(115		)
Interest expense	1			444			—			106			(245		)	306
Interest expense (income), net	1			380			(183		)	(7		)	—			191
Equity in net (income) loss of subsidiaries	(890		)	(911		)	(707		)	—			2,508			—
Income from operations before income taxes	814			585			890			1,186			(2,535		)	940
Provision (benefit) for income taxes	(6		)	(162		)	—			288			—			120
Net income	820			747			890			898			(2,535		)	820
Other comprehensive income (loss), net of tax	(172		)	(153		)	(172		)	(219		)	544			(172		)
Total comprehensive income	$	648		$	594		$	718		$	679		$	(1,991	)	$	648

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Balance Sheet

July 29, 2016

Medtronic Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (Medtronic, Inc.)		Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments			Total
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	46	$	55	$	2,959	$	—		$	3,060
Investments	—		—		—		9,750		—			9,750
Accounts receivable, net	—		—		—		5,357		—			5,357
Inventories	—		153		—		3,621		(194		)	3,580
Intercompany receivable	72		140,906		—		163,436		(304,414		)	—
Other current assets	5		178		—		1,597		(29		)	1,751
Total current assets	77		141,283		55		186,720		(304,637		)	23,498
Property, plant, and equipment, net	—		1,166		—		3,648		—			4,814
Goodwill	—		—		—		41,309		—			41,309
Other intangible assets, net	—		28		—		26,409		—			26,437
Tax assets	—		699		—		533		—			1,232
Investment in subsidiaries	53,531		70,405		40,609		—		(164,545		)	—
Intercompany loans receivable	3,000		9,425		21,991		28,924		(63,340		)	—
Other assets	—		540		—		771		—			1,311
Total assets	$	56,608	$	223,546	$	62,655	$	288,314	$	(532,522	)	$	98,601
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current debt obligations	$	—	$	500	$	975	$	472	$	—		$	1,947
Accounts payable	—		339		—		1,276		—			1,615
Intercompany payable	—		152,269		—		152,145		(304,414		)	—
Accrued compensation	67		362		—		776		—			1,205
Other accrued expenses	13		615		—		2,501		—			3,129
Total current liabilities	80		154,085		975		157,170		(304,414		)	7,896
Long-term debt	—		26,669		—		3,455		—			30,124
Accrued compensation and retirement benefits	—		1,319		—		451		—			1,770
Accrued income taxes	10		1,522		—		812		—			2,344
Long-term intercompany loans payable	5,626		10,125		15,151		32,438		(63,340		)	—
Deferred tax liabilities	—		—		—		3,790		—			3,790
Other liabilities	—		237		—		1,548		—			1,785
Total liabilities	5,716		193,957		16,126		199,664		(367,754		)	47,709
Shareholders’ equity	50,892		29,589		46,529		88,582		(164,768		)	50,824
Noncontrolling interests	$	—	$	—	$	—	$	68	$	—		$	68
Total equity	$	50,892	$	29,589	$	46,529	$	88,650	$	(164,768	)	$	50,892
Total liabilities and equity	$	56,608	$	223,546	$	62,655	$	288,314	$	(532,522	)	$	98,601

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Balance Sheet

April 29, 2016

Medtronic Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (Medtronic, Inc.)		Subsidiary Guarantor		Subsidiary Non-guarantors		Consolidating Adjustments			Total
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	55	$	—	$	2,821	$	—		$	2,876
Investments	—		—		—		9,758		—			9,758
Accounts receivable, net	—		—		—		5,562		—			5,562
Inventories	—		162		—		3,511		(200		)	3,473
Intercompany receivable	403		141,368		—		162,278		(304,049		)	—
Other current assets	24		271		—		1,636		—			1,931
Total current assets	427		141,856		—		185,566		(304,249		)	23,600
Property, plant, and equipment, net	—		1,139		—		3,702		—			4,841
Goodwill	—		—		—		41,500		—			41,500
Other intangible assets, net	—		31		—		26,868		—			26,899
Tax assets	—		690		—		693		—			1,383
Investment in subsidiaries	52,608		68,902		49,698		—		(171,208		)	—
Intercompany loans receivable	3,000		8,884		10,203		18,140		(40,227		)	—
Other assets	—		506		—		915		—			1,421
Total assets	$	56,035	$	222,008	$	59,901	$	277,384	$	(515,684	)	$	99,644
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current debt obligations	$	—	$	500	$	—	$	493	$	—		$	993
Accounts payable	—		288		—		1,421		—			1,709
Intercompany payable	—		151,687		—		152,362		(304,049		)	—
Accrued compensation	32		616		—		1,064		—			1,712
Other accrued expenses	12		243		—		2,496		—			2,751
Total current liabilities	44		153,334		—		157,836		(304,049		)	7,165
Long-term debt	—		26,646		—		3,463		—			30,109
Accrued compensation and retirement benefits	—		1,258		—		501		—			1,759
Accrued income taxes	10		1,422		—		1,471		—			2,903
Long-term intercompany loans payable	3,918		10,128		14,297		11,884		(40,227		)	—
Deferred tax liabilities	—		—		—		3,729		—			3,729
Other liabilities	—		202		—		1,714		—			1,916
Total liabilities	3,972		192,990		14,297		180,598		(344,276		)	47,581
Total shareholders' equity	52,063		29,018		45,604		96,786		(171,408		)	52,063
Total liabilities and shareholders' equity	$	56,035	$	222,008	$	59,901	$	277,384	$	(515,684	)	$	99,644

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Statement of Cash Flows

Three Months Ended July 29, 2016

Medtronic Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantor			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Operating Activities:
Net cash provided by (used in) operating activities	$	440		$	534		$	13		$	563		$	—		$	1,550
Investing Activities:
Acquisitions, net of cash acquired	—			—			—			(12		)	—			(12		)
Additions to property, plant, and equipment	—			—			—			(330		)	—			(330		)
Purchases of investments	—			—			—			(1,206		)	162			(1,044		)
Sales and maturities of investments	—			162			—			1,104			(162		)	1,104
Net (increase) decrease in intercompany loans	—			(541		)	(1,787		)	(785		)	3,113			—
Capital contribution paid	—			(162		)	—			—			162			—
Other investing activities, net	—			—			—			(2		)	—			(2		)
Net cash provided by (used in) investing activities	—			(541		)	(1,787		)	(1,231		)	3,275			(284		)
Financing Activities:
Acquisition-related contingent consideration	—			—			—			(11		)	—			(11		)
Change in current debt obligations, net	—			—			975			(49		)	—			926
Issuance of long-term debt	—			—			—			33			—			33
Payments on long-term debt	—			—			—			(17		)	—			(17		)
Dividends to shareholders	(599		)	—			—			—			—			(599		)
Issuance of ordinary shares	214			—			—			—			—			214
Repurchase of ordinary shares	(1,763		)	—			—			—			—			(1,763		)
Net intercompany loan borrowings (repayments)	1,708			(2		)	854			553			(3,113		)	—
Capital contribution	—			—			—			162			(162		)	—
Other financing activities	—			—			—			57			—			57
Net cash provided by (used in) financing activities	(440		)	(2		)	1,829			728			(3,275		)	(1,160		)
Effect of exchange rate changes on cash and cash equivalents	—			—			—			78			—			78
Net change in cash and cash equivalents	—			(9		)	55			138			—			184
Cash and cash equivalents at beginning of period	—			55			—			2,821			—			2,876
Cash and cash equivalents at end of period	$	—		$	46		$	55		$	2,959		$	—		$	3,060

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Statement of Cash Flows

Three Months Ended July 31, 2015

Medtronic Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantor			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Operating Activities:
Net cash provided by (used in) operating activities	$	(2	)	$	(330	)	$	178		$	970		$	—		$	816
Investing Activities:
Acquisitions, net of cash acquired	—			—			—			(179		)	—			(179		)
Additions to property, plant, and equipment	—			(62		)	—			(162		)	—			(224		)
Purchases of investments	—			—			—			(1,851		)	—			(1,851		)
Sales and maturities of investments	—			—			—			1,266			—			1,266
Net (increase) decrease in intercompany loans	(108		)	(99		)	(885		)	(135		)	1,227			—
Other investing activities, net	—			—			—			2			—			2
Net cash provided by (used in) investing activities	(108		)	(161		)	(885		)	(1,059		)	1,227			(986		)
Financing Activities:
Acquisition-related contingent consideration	—			—			—			(3		)	—			(3		)
Change in current debt obligations, net	—			—			429			—			—			429
Payments on long-term debt	—			—			—			(1,004		)	—			(1,004		)
Dividends to shareholders	(538		)	—			—			—			—			(538		)
Issuance of ordinary shares	98			—			—			—			—			98
Repurchase of ordinary shares	(750		)	—			—			—			—			(750		)
Net intercompany loan borrowings (repayments)	1,017			3			108			99			(1,227		)	—
Other financing activities	—			—			—			24			—			24
Net cash (used in) provided by financing activities	(173		)	3			537			(884		)	(1,227		)	(1,744		)
Effect of exchange rate changes on cash and cash equivalents	—			—			—			50			—			50
Net change in cash and cash equivalents	(283		)	(488		)	(170		)	(923		)	—			(1,864		)
Cash and cash equivalents at beginning of period	263			1,071			170			3,339			—			4,843
Cash and cash equivalents at end of period	$	(20	)	$	583		$	—		$	2,416		$	—		$	2,979

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Consolidating Statement of Comprehensive Income

Three Months Ended July 29, 2016

CIFSA Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (CIFSA)			Subsidiary Guarantor			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Net sales	$	—		$	—		$	—		$	7,166		$	—		$	7,166

Costs and expenses:
Cost of products sold				—			—			2,261			—			2,261
Research and development expense	—			—			—			556			—			556
Selling, general, and administrative expense	3			—			—			2,425			—			2,428
Restructuring charges, net	—			—			—			94			—			94
Certain litigation charges	—			—			—			82			—			82
Acquisition-related items	—			—			—			52			—			52
Amortization of intangible assets	—			—			—			487			—			487
Other expense, net	11			1			—			27			—			39
Operating profit (loss)	(14		)	(1		)	—			1,182			—			1,167

Interest income	—			(29		)	(157		)	(106		)	199			(93		)
Interest expense	16			32			1			422			(199		)	272
Interest expense (income), net	16			3			(156		)	316			—			179
Equity in net (income) loss of subsidiaries	(957		)	(805		)	(801		)	—			2,563			—
Income from operations before income taxes	927			801			957			866			(2,563		)	988
Provision (benefit) for income taxes	(2		)	—			—			61			—			59
Net income	929			801			957			805			(2,563		)	929
Other comprehensive income (loss), net of tax	(156		)	42			(156		)	(156		)	270			(156		)
Total comprehensive income	$	773		$	843		$	801		$	649		$	(2,293	)	$	773

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Consolidating Statement of Comprehensive Income

Three Months Ended July 31, 2015

CIFSA Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (CIFSA)			Subsidiary Guarantor			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Net sales	$	—		$	—		$	—		$	7,274		$	—		$	7,274

Costs and expenses:
Cost of products sold	—			—			—			2,456			—			2,456
Research and development expense	—			—			—			558			—			558
Selling, general, and administrative expense	2			—			—			2,447			—			2,449
Restructuring charges, net	—			—			—			67			—			67
Acquisition-related items	—			—			—			71			—			71
Amortization of intangible assets	—			—			—			481			—			481
Other (income) expense, net	73			—			—			(12		)	—			61
Operating profit (loss)	(75		)	—			—			1,206			—			1,131

Interest income	—			(164		)	(184		)	(118		)	351			(115		)
Interest expense	1			36			1			619			(351		)	306
Interest expense (income), net	1			(128		)	(183		)	501			—			191
Equity in net (income) loss of subsidiaries	(890		)	(77		)	(707		)	—			1,674			—
Income from operations before income taxes	814			205			890			705			(1,674		)	940
Provision (benefit) for income taxes	(6		)	—			—			126			—			120
Net income	820			205			890			579			(1,674		)	820
Other comprehensive income (loss), net of tax	(172		)	(66		)	(172		)	(172		)	410			(172		)
Total comprehensive income	648			139			718			407			(1,264		)	648

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Balance Sheet

July 29, 2016

CIFSA Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (CIFSA)		Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments			Total
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	85	$	55	$	2,920	$	—		$	3,060
Investments	—		—		—		9,750		—			9,750
Accounts receivable, net	—		—		—		5,357		—			5,357
Inventories	—		—		—		3,580		—			3,580
Intercompany receivable	72		—		60		—		(132		)	—
Other current assets	5		—		—		1,746		—			1,751
Total current assets	77		85		115		23,353		(132		)	23,498
Property, plant, and equipment, net	—		—		—		4,814		—			4,814
Goodwill	—		—		—		41,309		—			41,309
Other intangible assets, net	—		—		—		26,437		—			26,437
Tax assets	—		—		—		1,232		—			1,232
Investment in subsidiaries	53,531		21,282		39,285		—		(114,098		)	—
Intercompany loans receivable	3,000		3,963		23,256		17,885		(48,104		)	—
Other assets	—		—		—		1,311		—			1,311
Total assets	$	56,608	$	25,330	$	62,656	$	116,341	$	(162,334	)	$	98,601
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current debt obligations	$	—	$	—	$	975	$	972	$	—		$	1,947
Accounts payable	—		—		—		1,615		—			1,615
Intercompany payable	—		—		—		132		(132		)	—
Accrued compensation	67		—		—		1,138		—			1,205
Other accrued expenses	13		35		—		3,081		—			3,129
Total current liabilities	80		35		975		6,938		(132		)	7,896
Long-term debt	—		3,363		—		26,761		—			30,124
Accrued compensation and retirement benefits	—		—		—		1,770		—			1,770
Accrued income taxes	10		—		—		2,334		—			2,344
Long-term intercompany loans payable	5,626		4,107		15,152		23,219		(48,104		)	—
Deferred tax liabilities	—		—		—		3,790		—			3,790
Other liabilities	—		—		—		1,785		—			1,785
Total liabilities	5,716		7,505		16,127		66,597		(48,236		)	47,709
Shareholders’ equity	50,892		17,825		46,529		49,676		(114,098		)	50,824
Noncontrolling interests	—		—		—		68		—			68
Total equity	$	50,892	$	17,825	$	46,529	$	49,744	$	(114,098	)	$	50,892
Total liabilities and equity	$	56,608	$	25,330	$	62,656	$	116,341	$	(162,334	)	$	98,601

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Balance Sheet

April 29, 2016

CIFSA Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (CIFSA)		Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments			Total
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	208	$	—	$	2,668	$	—		$	2,876
Investments	—		—		—		9,758		—			9,758
Accounts receivable, net	—		—		—		5,562		—			5,562
Inventories	—		—		—		3,473		—			3,473
Intercompany receivable	403		—		61		—		(464		)	—
Other current assets	24		—		—		1,907		—			1,931
Total current assets	427		208		61		23,368		(464		)	23,600
Property, plant, and equipment, net	—		—		1		4,840		—			4,841
Goodwill	—		—		—		41,500		—			41,500
Other intangible assets, net	—		—		—		26,899		—			26,899
Tax assets	—		—		—		1,383		—			1,383
Investment in subsidiaries	52,608		36,477		48,375		—		(137,460		)	—
Intercompany loans receivable	3,000		8,253		11,465		27,724		(50,442		)	—
Other assets	—		—		—		1,421		—			1,421
Total assets	$	56,035	$	44,938	$	59,902	$	127,135	$	(188,366	)	$	99,644
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current debt obligations	$	—	$	—	$	—	$	993	$	—		$	993
Accounts payable	—		—		—		1,709		—			1,709
Intercompany payable	—		—		—		464		(464		)	—
Accrued compensation	32		—		—		1,680		—			1,712
Other accrued expenses	12		24		—		2,715		—			2,751
Total current liabilities	44		24		—		7,561		(464		)	7,165
Long-term debt	—		3,382		—		26,727		—			30,109
Accrued compensation and retirement benefits	—		—		—		1,759		—			1,759
Accrued income taxes	10		—		—		2,893		—			2,903
Long-term intercompany loans payable	3,918		14,689		14,298		17,537		(50,442		)	—
Deferred tax liabilities	—		—		—		3,729		—			3,729
Other liabilities	—		—		—		1,916		—			1,916
Total liabilities	3,972		18,095		14,298		62,122		(50,906		)	47,581
Total shareholders' equity	52,063		26,843		45,604		65,013		(137,460		)	52,063
Total liabilities and shareholders' equity	$	56,035	$	44,938	$	59,902	$	127,135	$	(188,366	)	$	99,644

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Statement of Cash Flows

Three Months Ended July 29, 2016

CIFSA Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (CIFSA)			Subsidiary Guarantors			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Operating Activities:
Net cash provided by (used in) operating activities	$	440		$	(7	)	$	—		$	1,117		$	—		$	1,550
Investing Activities:
Acquisitions, net of cash acquired	—			—			—			(12		)	—			(12		)
Additions to property, plant, and equipment	—			—			—			(330		)	—			(330		)
Purchases of investments	—			—			—			(1,044		)	—			(1,044		)
Sales and maturities of investments	—			—			—			1,104			—			1,104
Net (increase) decrease in intercompany loans receivable	—			4,290			(1,774		)	3,334			(5,850		)	—
Capital contributions paid	—			(325		)	—			—			325			—
Other investing activities, net	—			—			—			(2		)	—			(2		)
Net cash provided by (used in) investing activities	—			3,965			(1,774		)	3,050			(5,525		)	(284		)
Financing Activities:
Acquisition-related contingent consideration	—			—			—			(11		)	—			(11		)
Change in current debt obligations, net	—			—			975			(49		)	—			926
Issuance of long-term debt	—			—			—			33			—			33
Payments on long-term debt	—			—			—			(17		)	—			(17		)
Dividends to shareholders	(599		)	—			—			—			—			(599		)
Issuance of ordinary shares	214			—			—			—			—			214
Repurchase of ordinary shares	(1,763		)	—			—			—			—			(1,763		)
Net intercompany loan borrowings (repayments)	1,708			(4,081		)	854			(4,331		)	5,850			—
Intercompany dividend paid	—			—			—			—			—			—
Capital contributions received	—			—			—			325			(325		)	—
Other financing activities	—			—			—			57			—			57
Net cash provided by (used in) financing activities	(440		)	(4,081		)	1,829			(3,993		)	5,525			(1,160		)
Effect of exchange rate changes on cash and cash equivalents	—			—			—			78			—			78
Net change in cash and cash equivalents	—			(123		)	55			252			—			184
Cash and cash equivalents at beginning of period	—			208			—			2,668			—			2,876
Cash and cash equivalents at end of period	$	—		$	85		$	55		$	2,920		$	—		$	3,060

Medtronic plc

Notes to Consolidated Financial Statements

(Unaudited)

Condensed Consolidating Statement of Cash Flows

Three Months Ended July 31, 2015

CIFSA Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (CIFSA)			Subsidiary Guarantors			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Operating Activities:
Net cash provided by (used in) operating activities	$	(2	)	$	468		$	374		$	476		$	(500	)	$	816
Investing Activities:
Acquisitions, net of cash acquired	—			—			—			(179		)	—			(179		)
Additions to property, plant, and equipment	—			—			—			(224		)	—			(224		)
Purchases of investments	—			—			—			(1,851		)	—			(1,851		)
Sales and maturities of investments	—			—			—			1,266			—			1,266
Net (increase) decrease in intercompany loans receivable	(108		)	(195		)	(1,081		)	(3,628		)	5,012			—
Other investing activities, net	—			—			—			2			—			2
Net cash provided by (used in) investing activities	(108		)	(195		)	(1,081		)	(4,614		)	5,012			(986		)
Financing Activities:
Acquisition-related contingent consideration	—			—			—			(3		)	—			(3		)
Change in current debt obligations, net	—			—			429			—			—			429
Issuance of long-term debt	—			—			—			—			—			—
Payments on long-term debt	—			(1,000		)	—			(4		)	—			(1,004		)
Dividends to shareholders	(538		)	—			—			—			—			(538		)
Issuance of ordinary shares	98			—			—			—			—			98
Repurchase of ordinary shares	(750		)	—			—			—			—			(750		)
Net intercompany loan borrowings (repayments)	1,017			179			108			3,708			(5,012		)	—
Intercompany dividend paid	—			—			—			(500		)	500			—
Other financing activities	—			—			—			24			—			24
Net cash provided by (used in) financing activities	(173		)	(821		)	537			3,225			(4,512		)	(1,744		)
Effect of exchange rate changes on cash and cash equivalents	—			—			—			50			—			50
Net change in cash and cash equivalents	(283		)	(548		)	(170		)	(863		)	—			(1,864		)
Cash and cash equivalents at beginning of period	263			728			170			3,682			—			4,843
Cash and cash equivalents at end of period	$	(20	)	$	180		$	—		$	2,819		$	—		$	2,979

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

UNDERSTANDING OUR FINANCIAL INFORMATION

The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company, or we, us, or our). For a full understanding of financial condition and results of operations, you should read this discussion along with management’s discussion and analysis of financial condition and results of operations in our Annual Report on Form 10-K for the fiscal year ended April 29, 2016. In addition, you should read this discussion along with our consolidated financial statements and related notes thereto as of July 29, 2016.

Financial Trends

Throughout this management’s discussion and analysis, we present certain financial measures that management uses to evaluate the operational performance of the Company and as a basis for strategic planning; however, such financial measures are not presented in our financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S.) (U.S. GAAP). These financial measures are considered "non-GAAP financial measures."

Management uses non-GAAP financial measures to facilitate management’s review of the operational performance of the Company and as a basis for strategic planning. Management believes that non-GAAP financial measures provide useful information to investors regarding the underlying business trends and performance of the Company’s ongoing operations and are useful for period over period comparisons of such operations. The non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations. Investors should not consider results reflecting non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with U.S. GAAP and are cautioned that Medtronic may calculate results reflecting non-GAAP financial measures in a manner that is different from other companies.

The GAAP to Non-GAAP Reconciliation presents non-GAAP financial measures that exclude the impact of charges or gains that contribute to or reduce earnings and may affect financial trends but which include charges or benefits that result from transactions or events that management believes may or may not recur with similar materiality or impact to our operations in future periods (Non-GAAP Adjustments).

In the event there is a Non-GAAP Adjustment recognized in our operating results, the tax cost or benefit attributable to that item is separately calculated and recorded. Because the effective rate can be significantly impacted by these Non-GAAP Adjustments that take place in the period, we often refer to our tax rate using both the effective rate and the non-GAAP nominal tax rate (Non-GAAP Nominal Tax Rate). The Non-GAAP Nominal Tax Rate is calculated as the provision for income taxes, adjusted for the impact of Non-GAAP Adjustments, as a percentage of income from operations before income taxes, excluding Non-GAAP Adjustments.

Free cash flow is a non-GAAP financial measure calculated by subtracting property, plant, and equipment additions from operating cash flows.

Refer to the “GAAP to Non-GAAP Reconciliation," "Income Taxes," and "Summary of Cash Flows" sections for reconciliations of our results of operations prepared in accordance with U.S. GAAP to the adjusted non-GAAP measurements considered by management.

EXECUTIVE LEVEL OVERVIEW

Medtronic is among the world's largest medical technology, services, and solutions companies - alleviating pain, restoring health, and extending life for millions of people around the world. We employ more than 88,000 full-time employees, serving hospitals, physicians, clinicians, and patients in approximately 160 countries worldwide. Our primary products include those for cardiac rhythm disorders, cardiovascular disease, advanced and general surgical care, respiratory and monitoring solutions, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, and ear, nose, and throat and diabetes conditions.

Net income for the three months ended July 29, 2016 was $929 million, or $0.66 per diluted share, as compared to net income of $820 million, or $0.57 per diluted share, for the three months ended July 31, 2015, representing increases of 13 percent and 16 percent, respectively.

The table below illustrates net sales by operating segment for the three months ended July 29, 2016 and July 31, 2015:



	Three months ended
(in millions)	July 29, 2016		July 31, 2015		% Change
Cardiac and Vascular Group	$	2,518	$	2,567	(2	)%
Minimally Invasive Therapies Group	2,424		2,456		(1	)
Restorative Therapies Group	1,772		1,806		(2	)
Diabetes Group	452		445		2
Total Net Sales	$	7,166	$	7,274	(1	)%

Our change in net sales for the three months ended July 29, 2016 was unfavorably impacted by approximately $450 million due to an additional selling week during the first quarter of fiscal year 2016, resulting from our 52/53 week fiscal year calendar. Currency translation had an unfavorable impact of $7 million on net sales for the three months ended July 29, 2016, as compared to the same period in the prior fiscal year. The Cardiac and Vascular Group’s performance for the three months ended July 29, 2016 was primarily a result of the Cardiac Rhythm and Heart Failure outperforming the market in core implantables and continued strength in the Aortic Peripheral Vascular business from the Endurant IIs aortic stent graft, the Heli-FX EndoAnchor System and Valiance Captivia thoracic stent graft. Minimally Invasive Therapies Group net sales for the three months ended July 29, 2016 was impacted by consistent performance in Surgical Solutions business and Patient Monitoring & Recovery by returning the Puritan Bennett 980 ventilator and Capnostream 20 capnography monitor to the market after shipping holds. The Restorative Therapies Group’s performance for the three months ended July 29, 2016 was impacted by strong results in the Brain Therapies and Specialty Therapies businesses offset by declines in Spine and Pain Therapies. The Diabetes Group's growth for the three months ended July 29, 2016 was due to growth in markets outside the U.S. See our discussion in the “Net Sales” section of this management's discussion and analysis for more information on the results of our operating segments.

GAAP to Non-GAAP Reconciliation The following is a reconciliation of our net sales, operating profit, income from operations before income taxes, net income, provision for income taxes, and effective tax rate prepared in accordance with U.S. GAAP to those results after giving effect to Non-GAAP Adjustments. We have provided these non-GAAP financial measures because we believe they provide meaningful information regarding our results on a consistent and comparable basis for the periods presented. Management uses these non-GAAP financial measures to facilitate management's review of the operational performance of the Company and as a basis for strategic planning. Management believes that the resulting non-GAAP financial measures provide useful information to investors regarding the underlying business trends and performance of the Company's ongoing operations and are useful for period over period comparisons of such operations. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations. Refer to our discussion in the "Cost and Expenses" and "Income Taxes" sections of this management's discussion and analysis for more information on these reconciling items. Investors should not consider results reflecting non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with U.S. GAAP and are cautioned that Medtronic may calculate results reflecting non-GAAP financial measures in a manner that is different from other companies.

The table below presents our GAAP to Non-GAAP reconciliation for the three months ended July 29, 2016 and July 31, 2015:



	Three months ended July 29, 2016
(in millions)	Net Sales		Operating Profit		Income from Operations Before Income Taxes		Net Income			Provision for Income Taxes⁽¹⁾		Effective Tax Rate
GAAP	$	7,166	$	1,167	$	988	$	929		$	59	6.0	%
Non-GAAP Adjustments:
Restructuring charges, net	—		104		104		79			25		24.0
Certain litigation charges	—		82		82		52			30		36.6
Acquisition-related items	—		52		52		39			13		25.0
Amortization of intangible assets	—		487		487		376			111		22.8
Certain tax adjustments	—		—		—		(31		)	31		—
Non-GAAP	$	7,166	$	1,892	$	1,713	$	1,444		$	269	15.7	%

	Three months ended July 31, 2015
(in millions)	Net Sales		Operating Profit		Income from Operations Before Income Taxes		Net Income			Provision for Income Taxes⁽¹⁾		Effective Tax Rate
GAAP	$	7,274	$	1,131	$	940	$	820		$	120	12.8	%
Non-GAAP Adjustments:
Impact of inventory step-up	—		226		226		165			61		27.0
Restructuring charges, net	—		67		67		52			15		22.4
Acquisition-related items	—		71		71		53			18		25.4
Amortization of intangible assets	—		481		481		372			109		22.7
Non-GAAP	$	7,274	$	1,976	$	1,785	$	1,462		$	323	18.1	%


(1)	The tax effect of each Non-GAAP Adjustment is based on the jurisdictions in which the expense (income) is incurred and the tax laws in effect for each such jurisdiction.

CRITICAL ACCOUNTING ESTIMATES

We have used various accounting policies to prepare the consolidated financial statements in accordance with U.S. GAAP. Our most significant accounting policies are disclosed in Note 1 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended April 29, 2016.

The preparation of the consolidated financial statements, in conformity with U.S. GAAP, requires management to use judgment in making estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. These estimates reflect managements' best judgment about economic and market conditions and their potential effects on the valuation and/or carrying value of assets and liabilities based upon relevant information available. We base our estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

Our critical accounting estimates include the following:

Revenue Recognition Based upon the lag time between the original sale to distributors at list price and the related distributor rebate earned at time of sale to the end customer and the judgments involved in estimating such rebates, we consider certain Minimally Invasive Therapies Group price adjustment rebates to be a critical accounting estimate. We adjust reserves to reflect differences between estimated and actual experience, and record such adjustment as a reduction of sales in the period of adjustment. Adjustments to recorded reserves have not been significant. Price adjustment rebates charged against gross sales in the first quarter of fiscal years 2017 and 2016 were $736 million and $737 million, respectively.

Litigation Contingencies We are involved in a number of legal actions involving product liability, intellectual property disputes, shareholder related matters, environmental proceedings, income tax disputes, and governmental proceedings and investigations in the United States and around the world. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief (including injunctions barring the sale of products that are the subject of the lawsuit), that could require significant expenditures or result in lost revenues. Estimates of probable losses resulting from litigation, governmental proceedings, and income tax matters involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery; involve unsubstantiated or indeterminate claims for damages; potentially involve penalties, fines, or punitive damages; or could result in a change in business practice. Our significant legal proceedings are discussed in Note 15 to the current period's consolidated financial statements. While it is not possible to predict the outcome for most of the matters discussed in Note 15 to the current period's consolidated financial statements, we believe it is possible that costs associated with these matters could have a material adverse impact on our consolidated earnings, financial position, and/or cash flows.

Income Tax Reserves We establish reserves when, despite our belief that our tax return positions are fully supportable, we believe that certain positions are likely to be challenged and that we may or may not prevail. These reserves are established and adjusted in accordance with the principles of U.S. GAAP. Under U.S. GAAP, if we determine that a tax position is more likely than not of being sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50 percent likely of being realized upon settlement. We presume that all tax positions will be examined by a taxing authority with full knowledge of all relevant information. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions across our global operations. We regularly monitor our tax positions and tax liabilities. We reevaluate the technical merits of our tax positions and recognize an uncertain tax benefit, or derecognize a previously recorded tax benefit, when (i) there is a completion of a tax audit, (ii) effective settlement of an issue, (iii) there is a change in applicable tax law including a tax case or legislative guidance, or (iv) there is an expiration of the statute of limitations. Significant judgment is required in accounting for tax reserves. Although we believe that we have adequately provided for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on our effective tax rate, consolidated earnings, financial position and/or cash flows.

Valuation of Intangible Assets and Goodwill When we acquire a business, the assets acquired and liabilities assumed are recorded at their respective fair values as of the acquisition date. Goodwill is the excess of the purchase price consideration over the estimated fair value of net assets of acquired businesses. Intangible assets include patents, trademarks, tradenames, customer relationships, purchased technology, and IPR&D. Determining the fair value of intangible assets acquired as part of a business combination requires us to make significant estimates. These estimates include the amount and timing of projected future cash flows of each project or technology, the discount rate used to discount those cash flows to present value, the assessment of the asset’s life cycle, and the consideration of legal, technical, regulatory, economic, and competitive risks.

The test for goodwill impairment requires us to make several estimates about fair value, most of which are based on projected future cash flows. Our estimates associated with the goodwill impairment test are considered critical due to the amount of goodwill recorded on our consolidated balance sheets and the judgment required in determining fair value, including projected future cash flows. The Company assesses the impairment of goodwill annually in the third quarter at the reporting unit level and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Goodwill was $41.3 billion and $41.5 billion at July 29, 2016 and April 29, 2016, respectively.

We test definite-lived intangible assets for impairment when an event occurs or circumstances change that would indicate the carrying amount of the assets or asset group may be impaired. Our tests are based on future cash flows that require significant judgment with respect to future revenue and expense growth rates, appropriate discount rate, asset groupings, and other assumptions and estimates. We use estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates due to a number of factors including, among others, changes in competitive conditions, timing of regulatory approval, results of clinical trials, changes in worldwide economic conditions, and fluctuations in currency exchange rates. Definite-lived intangible assets, net of accumulated amortization, were $25.8 billion and $26.2 billion at July 29, 2016 and April 29, 2016, respectively.

We assess the impairment of indefinite-lived intangibles annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Our impairment tests of indefinite-lived intangibles require us to make several estimates about fair value, most of which are based on projected future cash flows. Indefinite-lived intangible assets, were $638 million and $721 million at July 29, 2016 and April 29, 2016, respectively.

Contingent Consideration Contingent consideration is recorded at the acquisition date at estimated fair value and is remeasured each reporting period with the change in fair value recognized as income or expense within acquisition-related items in our consolidated statements of income. Changes to the fair value of contingent consideration can result from changes in the timing and amount of revenue estimates, in the timing or probability of achieving the milestones which trigger payment, or in discount rates. The fair value of contingent consideration was $379 million and $377 million at July 29, 2016 and April 29, 2016, respectively.

NEW ACCOUNTING PRONOUNCEMENTS

Information regarding new accounting pronouncements is included in Note 2 to the current period's consolidated financial statements.

ACQUISITIONS

Information regarding acquisitions is included in Note 3 to the current period's consolidated financial statements.

NET SALES

The table below illustrates net sales by operating segment and division for the three months ended July 29, 2016 and July 31, 2015:



	Three months ended
(in millions)	July 29, 2016		July 31, 2015		% Change
Cardiac Rhythm & Heart Failure	$	1,334	$	1,369	(3	)%
Coronary & Structural Heart	762		788		(3	)
Aortic & Peripheral Vascular	422		410		3
Total Cardiac and Vascular Group	2,518		2,567		(2	)
Surgical Solutions	1,348		1,352		—
Patient Monitoring & Recovery	1,076		1,104		(3	)
Total Minimally Invasive Therapies Group	2,424		2,456		(1	)
Spine	645		685		(6	)
Brain Therapies	489		466		5
Specialty Therapies	356		346		3
Pain Therapies	282		309		(9	)
Total Restorative Therapies Group	1,772		1,806		(2	)
Diabetes Group	452		445		2
Total	$	7,166	$	7,274	(1	)%

Cardiac and Vascular Group

The Cardiac and Vascular Group’s products, with specific focus on comprehensive disease management, include pacemakers, insertable and external cardiac monitors, cardiac resynchronization therapy devices (CRT-D), implantable cardioverter defibrillators (ICD), leads and delivery systems, ablation products, electrophysiology catheters, products for the treatment of atrial fibrillation, information systems for the management of patients with Cardiac Rhythm & Heart Failure devices, products designed to reduce surgical site infections, coronary and peripheral stents, balloon, and related delivery systems, endovascular stent graft systems, heart valve replacement technologies, cardiac tissue ablation systems, and open heart and coronary bypass grafting surgical products. The Cardiac and Vascular Group also includes Care Management Services and Cath Lab Managed Services (CLMS) within the Cardiac Rhythm & Heart Failure division. The Cardiac and Vascular Group’s net sales for the three months ended July 29, 2016 were $2.5 billion, a decrease of 2 percent as compared to the same period in the prior fiscal year. Currency translation had an unfavorable impact on net sales for the three months ended July 29, 2016 of $7 million as a result of the change in exchange rates from the same period in the prior fiscal year. The Cardiac and Vascular Group's performance for the three months ended July 29, 2016, as compared to the same period in the prior fiscal year, benefited from strong net sales across all three divisions, offset by the unfavorable impact of the additional selling week during the first quarter of fiscal year 2016. See the more detailed discussion of each division's performance below.

Cardiac Rhythm & Heart Failure net sales for the three months ended July 29, 2016 were $1.3 billion, a decrease of 3 percent as compared to the same period in the prior fiscal year. Cardiac Rhythm & Heart Failure net sales for the three months ended July 29, 2016 were driven by strong growth in AF Solutions, with the continued global acceptance of our Arctic Front Advance Cardiac CryoAblation Catheter (Arctic Front) system. Additionally, net sales were driven by the continued adoption of the Reveal LINQ insertable cardiac monitor, and continued growth of the Amplia MRI and Compia MRI Quad CRT-D, Evera MRI ICD, and Micra TPS pacemaker.

Coronary & Structural Heart net sales for the three months ended July 29, 2016 were $762 million, a decrease of 3 percent as compared to the same period in the prior fiscal year. Coronary & Structural Heart net sales for the three months ended July 29, 2016 were driven by the CoreValve Evolut R recapturable system growth in international markets offset by limitations in the U.S. resulting from the lack of a large size Evolut R. In addition, net sales of Coronary & Structural Heart were driven by drug-eluting stents, largely driven by the Resolute Onyx drug-eluting stent in Europe and emerging markets, and the Euphora Non-Compliant and Semi-Compliant Balloon Dilatation Catheters. Net sales for Coronary & Structural Heart were partially offset by continued pricing pressures and competition in the U.S. in our Coronary business.

Aortic & Peripheral Vascular net sales for the three months ended July 29, 2016 were $422 million, an increase of 3 percent as compared to the same period in the prior fiscal year. The Aortic & Peripheral Vascular division net sales for the three months ended July 29, 2016 was driven by strong worldwide growth of the IN.PACT Admiral drug-coated balloon worldwide, as well as continued sales strength in Valiant Captiva Thoracic Stent Graft System, Aptus Heli-FX EndoAnchor, and Endurant IIs aortic stent graft. EndoVenous Superficial & Embolization also contributed strong growth for the quarter.

Looking ahead, we expect our Cardiac and Vascular Group could be affected by the following:


•	Changes in procedural volumes, competitive and pricing pressure, reimbursement challenges, impacts from changes in the mix of our product offerings, the timing of product registration approvals, and fluctuations in currency exchange rates.

•

Closing of our acquisition of HeartWare International, Inc. (HeartWare), a leading innovator of implantable heart pumps, or ventricular assist devices (VAD), to treat patients around the world suffering from advanced heart failure, on August 23, 2016. The acquisition of HeartWare broadens the Medtronic portfolio of therapies, diagnostic tools and services for patients suffering from heart failure and is part of the Company's therapy innovation strategy to surround the physician with innovative products while focusing on patients and disease states.


•	Acceptance and future growth of the CRT-P quadripolar pacing system, which is expected to launch in Europe late in fiscal year 2017.


•	Acceptance and future growth of the Claria MRI CRT-D system with EffectivCRT Diagnostic and Effective CRT during AF algorithm, which is expected to launch in the U.S. and Japan in fiscal year 2017.


•	Continued future growth from Reveal LINQ, our next-generation insertable cardiac monitor, which is expected to launch in Japan in the second quarter of fiscal year 2017.

•

Continued future growth of our Micra transcatheter pacing system, which started shipments and physician training in the U.S. in the first quarter of fiscal year 2017. Micra is a miniaturized single chamber pacemaker system that is delivered through the femoral vein and is implanted in the right ventricle of the heart. The system does not use a lead and does not have a subcutaneous device pocket underneath the skin as with conventional pacemaker systems. We expect to obtain a National Coverage Decision from Centers for Medicare & Medicaid Services for this transformative therapy by the end of fiscal year 2017.


•	Continued acceptance and future growth from Care Management Services as post-acute care services become even more critical in bundled payment models for different interventions.


•	Anticipated approval and launch of Evolut R XL valve in early calendar year 2017. Currently we are negatively impacted in the U.S. by the lack of a large size Evolut R, our next-generation recapturable system with differentiated 14-French equivalent delivery system.


•	Anticipated FDA approval and market release of Resolute Onyx in the U.S. in late fiscal year 2017 or early fiscal year 2018. Resolute Onyx builds on the Resolute Integrity drug-eluting coronary stent with thinner struts to improve deliverability and is the first stent to feature our CoreWire technology, allowing greater visibility during the procedure.

•

Acceptance of the IN.PACT Admiral drug-coated balloon for the treatment of peripheral artery disease in the upper leg. The IN.PACT Admiral drug-coated balloon received CE Mark approval in January 2016 for arteriovenous access to help maintain hemodialysis access in patients with end-stage renal disease. We expect additional growth in fiscal year 2017 from the launch of the longer length 150mm sized, which occurred in the first quarter of fiscal year 2017.

Minimally Invasive Therapies Group

The Minimally Invasive Therapies Group’s technologies and products span the entire continuum of care with a focus on diseases of the gastrointestinal tract, lungs, pelvic region, kidneys, obesity, and preventable complications. The products include those for advanced and general surgical care, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, advanced ablation, and interventional lung, ventilators, capnography, airway products, sensors, monitors, compression, dialysis, enteral feeding, wound care, and medical surgical products. The Minimally Invasive Therapies Group’s net sales for the three months ended July 29, 2016 were $2.4 billion, a decrease of one percent as compared to the same period in the prior fiscal year. Currency translation had a favorable impact on net sales of $2 million as a result of the change in exchange rates from the same period in the prior fiscal year, and performance was unfavorably impacted by an additional selling week during the first quarter of fiscal year 2016. See the more detailed discussion of each business’s performance below.

Surgical Solutions net sales for the three months ended July 29, 2016 were $1.3 billion, which was flat as compared to the same period in the prior fiscal year. The net sales performance in Surgical Solutions was mainly attributable to stapling and energy. Stapling products results benefitted from continued worldwide market adoption of the Endo GIA Reinforced Reload and Tri-Staple, Energy products benefitted from continued strong adoption of the LigaSure Maryland Jaw and Valleylab FT10 Energy Platform. In addition, Early Technologies sales performance was driven by our gastrointestinal diagnostic product line.

Patient Monitoring & Recovery net sales for the three months ended July 29, 2016 were $1.1 billion, a decrease of 3 percent as compared to the same period in the prior fiscal year. Net sales contributions in Patient Monitoring & Recovery were driven mainly by U.S. sales within Respiratory and Patient Monitoring, Deep Vein Thrombosis, Nutritional Insufficiency, Patient Care, and Renal Care Solutions. Respiratory and Patient Monitoring performance was attributable to sensors, airway products, and acute ventilator sales. Deep Vein Thrombosis/ Nutritional Insufficiency growth was attributable to compression and enteral feeding sales. Patient Care net sales performance was primarily due to sales of SharpSafety product lines, electrodes, incontinence, and wound care products. Renal Care Solution sales were primarily attributable to sales of dialysis products and the acquisition of Bellco. Sales were also impacted by the return of the Puritan Bennett 980 ventilator and Capnostream 20 capnography monitor to the market after shipping holds.

Looking ahead, we expect our Minimally Invasive Therapies Group could be affected by the following:


•	Changes in procedural volumes, competitive and pricing pressure, reimbursement challenges, impacts from changes in the mix of our product offerings, the timing of product registration approvals, and fluctuations in currency exchange rates.

•

Continued acceptance and future growth of Open-to-Minimally Invasive Surgery (MIS) techniques and tools supported by our efforts to transition open surgery to MIS. The Open to MIS initiative focuses on establishing our presence in and working to optimize open surgery globally, while capturing the market opportunity that exists in transitioning open procedures to MIS, whether through traditional MIS, or advanced technologies like robotics. To achieve this transition, we are focused on product training, surgical skill training and continued therapy innovation to advance MIS.

•

Our ability to create markets and drive product and procedures into emerging markets. We have high quality and cost-effective surgical products designed for customers in emerging markets such as the ReliaMax reusable stapler, which is reposable (part reusable, part disposable), and the ValleyLab LS10 single channel vessel sealing generator, which is compatible with our line of LigaSure instruments and designed for simplified use and affordability.

•

Continued acceptance and future growth within the end stage renal disease market. The population of patients treated for end stage renal disease globally is expected to double over the next decade. We will grow our therapy innovation with scalable and affordable dialysis delivery and investing in vascular creation and maintenance technologies. Our focus on end stage renal disease will benefit from the acquisition of Bellco, a pioneer in hermodialysis treatment solutions. In addition, the HD multi-pass system, expected to launch in fiscal year 2018, reduces infrastructure by requiring less water, has less start-up costs, and offers high quality ultrapure dialysate treatment.


•	Continued elevation of the standard of care for respiratory compromise, a progressive condition impacting a patient’s ability to breathe effectively. The Capnostream35 is expected to launch in fiscal year 2017.

•

Continued acceptance and growth in respiratory care, ventilation and airway management, patient monitoring, and homecare. Key products in this area include the Puritan Bennett 980 ventilator, Microstream Capnography bedside capnography monitor, portable monitor with Nellcor pulse oximetry system with OxiMax technology and the Nellcor Respiratory Compromise monitor with vital signs of SpO2, pulse rate, End-Tidal CO2, and Respiratory Rate.

•

Continued and future acceptance of Early Technologies and creation of less invasive standards of care, including the areas of GI solutions, advanced ablation, and interventional lung solutions. Recently launched products include the PillCam COLON capsule endoscopy, the Barrx platform through ablation with the Barrx 360 Express catheter, the Emprint ablation system with Thermosphere Technology which maintains predictable spherical ablation zones throughout procedures reducing procedure time and cost, the superDimension GenCut core biopsy system and the Triple Needle Cytology Brush, a lung tissue biopsy tools for use with the superDimension navigation system. The superDimension system enables a minimally invasive approach to accessing difficult-to-reach areas of the lung, which can aid in the diagnosis of lung cancer.


•	Expanding the use of less invasive treatments and furthering our commitment to improving options for women with abnormal uterine bleeding with our recent acquisition of a Smith & Nephew's gynecology business. The addition will expand and strengthen the Minimally Invasive Therapies Group’s surgical offerings and will further complement the existing global gynecology business.


•	Future acceptance of the Signia Stapling System, expected to launch in fiscal year 2017. The single-hand use increases patient focus and consistent staple lines reduce leaks and tissue trauma.

Restorative Therapies Group

The Restorative Therapies Group includes products for various areas of the spine, bone graft substitutes, biologic products, trauma, implantable neurostimulation therapies and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder (OCD), overactive bladder, urinary retention, fecal incontinence and gastroparesis, products to treat conditions of the ear, nose, and throat, and systems that incorporate advanced energy surgical instruments. Additionally, this group manufactures and sells image-guided surgery and intra-operative imaging systems, and also manufactures and markets products and therapies to treat diseases of the vasculature in and around the brain and includes sales of coils, neurovascular stents and flow diversion products. The Restorative Therapies Group’s net sales for the three months ended July 29, 2016 were $1.8 billion, a decrease of 2 percent as compared to the same period in the prior fiscal year. Performance was unfavorably impacted by the additional selling week during the first quarter of fiscal year 2016. The Restorative Therapies Group’s performance for the three months ended July 29, 2016 was driven by strong Brain Therapies and Specialty Therapies growth, offset by declines in Spine and Pain Therapies. See the more detailed discussion of each division’s performance below.

Spine net sales for the three months ended July 29, 2016 were $645 million, a decrease of 6 percent compared to the same period in the prior fiscal year. The decrease in Spine net sales for the three months ended July 29, 2016 was due to declines in international BMP due to the InductOs stop shipment in Europe and weakness in the Middle East, partially offset by core spine driven by new product launches in TL Interbody and U.S. Infuse growth.

Brain Therapies net sales for the three months ended July 29, 2016 were $489 million, an increase of 5 percent compared to the same period in the prior fiscal year. The growth in net sales was driven by strong performance from the Neurovascular business, with new products, such as our PipelineFlex device and Solitaire FR revascularization device, along with Neurovascular access products. The increase in net sales was also driven by growth in Neurosurgery with the O-arm O2 sales growth in the U.S. and StealthStation sales growth internationally.

Specialty Therapies net sales for the three months ended July 29, 2016 were $356 million, an increase of 3 percent compared to the same period in the prior fiscal year. The growth in net sales was driven by strong growth in Advanced Energy and solid growth in ENT and Pelvic Health. Net sales growth in Advanced Energy was driven by strong growth from the Aquamantys Transcollation and PEAK PlasmaBlade technologies, as well as disposables and service revenue. Net sales growth in ENT continues to benefit from the adoption of new products, including the Straightshot M5 Microdebrider, and NuVent sinus balloons.

Pain Therapies net sales for the three months ended July 29, 2016 were $282 million, a decrease of 9 percent compared to the same period in the prior fiscal year. The decrease in net sales was driven by decreases in our Spinal Cord Stimulation products, partially offset by increases in Drug Pumps, as well as growth in Interventional due to the OsteoCool RF Spinal Tumor ablation system.

Looking ahead, we expect our Restorative Therapies Group could be affected by the following:


•	Changes in procedural volumes, competitive and pricing pressure, reimbursement challenges, impacts from changes in the mix of our product offerings, the timing of product registration approvals, and fluctuations in currency exchange rates.


•	Continued commercial integration in the Restorative Therapies Group and continued market acceptance of our new integrated solutions through the Surgical Synergy program, which integrates our spinal implants and imaging and navigation equipment.

•

Market acceptance and continued adoption of innovative new products, such as our CD Horizon Solera Voyager system, our ELEVATE expandable interbody cages, and our OLIF25 and OLIF51 procedure solutions, both of which have recently been augmented with new implant technology. During July, we received U.S. FDA approval for our Prestige LP which we expect will help drive adoption of cervical disc arthroplasty procedures in the U.S.

•

Continued pricing and competitive pressures on premium balloon kyphoplasty (BKP) within Interventional Spine. Though we remain focused on communicating the clinical and economic benefits for premium BKP, we expect pressure in several markets to continue. We believe opportunities for growth exist in the broader vertebral compression fracture (VCF) and adjacent markets, and continue to pursue the development of other therapies to treat more patients with VCF, including the recent U.S. launches of both the Kyphon V vertebroplasty system and the Osteocool tumor ablation system.


•	Acceptance of Kanghui's broad portfolio of trauma, spine, and large-joint reconstruction products focused on the growing global value segment.


•	Continued acceptance and adoption rates of stimulators and leads approved to treat chronic pain in major markets around the world.


•	Ongoing obligations under the U.S. FDA consent decree entered in April 2015 relating to the SynchroMed drug infusion system and the Neuromodulation quality system.

•

Continued and future acceptance of our current indications for Medtronic DBS Therapy for the treatment of movement disorders, epilepsy (approved in Europe), and OCD. The DBS Therapy portfolio includes Activa PC, our small and advanced primary cell battery, and Activa RC, a rechargeable DBS device. We anticipate continued competitive pressures in Europe and expect competition to enter the U.S. market in the coming year.


•	Continued acceptance and growth of our specialty therapies, including InterStim Therapy for the treatment of the symptoms of overactive bladder, urinary retention, and bowel incontinence, and Advanced Energy products and strategies to focus on its four core markets of orthopedic, spine, breast surgery, and CRDM replacements.


•	Continued growth from Neurosurgery StealthStation S7 and O-Arm Imaging Systems, Midas and ENT power systems, and intraoperative nerve monitoring during surgical procedures utilizing the NIM-Response 3.0 during head and neck surgical procedures. Additionally, continued growth in nerve monitoring utilizing the NIM Eclipse system during spinal surgical procedures.


•	Continued acceptance and growth of the Solitare FR revascularization device for treatment of acute ischemic stroke and the Pipeline Embolization Devices, endovascular treatments for large or giant wide-necked brain aneurysms.


•	Efficiencies gained from fiscal year 2017 reorganization to provide a stronger focus on the diseases and conditions that we serve to further innovate, integrate platforms and leverage breadth of product portfolio across the Restorative Therapies Group.


•	Successful placement of robotic units and associated market adoption of robot-assisted Spine procedures, under the recent co-promotion agreement with Mazor Robotics.

Diabetes Group

The Diabetes Group's products include insulin pumps, continuous glucose monitoring (CGM) systems, insulin pump consumables, and therapy management software. The Diabetes Group’s net sales for the three months ended July 29, 2016 were $452 million, an increase of 2 percent as compared to the same period in the prior fiscal year. Currency translation had an unfavorable impact on net sales for the three months ended July 29, 2016 of $2 million as a result of the change in exchange rates from the same period in the prior fiscal year. The Diabetes Group's net sales for the three months ended July 29, 2016 was favorably impacted by growth in international markets, offset by the impact of the additional selling week during the first quarter of fiscal year 2016. The Diabetes Group's performance in international markets was favorably affected by the ongoing launch of our next-generation MiniMed 640G System with the Enhanced Enlite sensor.

Looking ahead, we expect our Diabetes Group could be affected by the following:


•	Competitive and pricing pressure, reimbursement challenges, impacts from changes in the mix of our product offerings, the timing of product registration approvals, and fluctuations in currency exchange rates.


•	Changes in medical reimbursement policies and programs. Continued acceptance and improved reimbursement of CGM technologies.


•	Acceptance of the MiniMed 630G System, which includes the insulin pump and Enlite CGM sensor. This system launched in the U.S. during August 2016 and combines proprietary SmartGaurd technology featured in the MiniMed 530G system with brand new user-friendly design.


•	Continued acceptance from both physicians and patients of insulin-pump and CGM therapy.

•

Continued acceptance and future growth from our next-generation pump systems, the MiniMed 640G with SmartGuard predictive low-glucose management, which has launched in Europe, Australia, and select countries in Latin America and Asia, and the MiniMed 620G, the first integrated system customized for the Japanese market. The Company filed its premarket approval to the U.S. FDA for the first hybrid closed loop system in June 2016.


•	Continued acceptance and future growth of MiniMed Connect, which allows users to view their insulin pump and CGM data on a smartphone and provides remote monitoring and text message notifications.


•	Selection by UnitedHealthcare as the preferred in-network provider of insulin pumps, giving their members access to our advanced diabetes technology and comprehensive support services.

OPERATIONS BY MARKET GEOGRAPHY

The table below illustrates net sales by market geography for each of our operating segments for the three months ended July 29, 2016 and July 31, 2015:



	Three months ended July 29, 2016						Three months ended July 31, 2015
(in millions)	U.S.		Non-U.S. Developed Markets		Emerging Markets		U.S.		Non-U.S. Developed Markets		Emerging Markets
Cardiac and Vascular Group	$	1,297	$	829	$	392	$	1,352	$	830	$	385
Minimally Invasive Therapies Group	1,235		863		326		1,292		841		323
Restorative Therapies Group	1,207		384		181		1,224		386		196
Diabetes Group	263		155		34		274		140		31
Total	$	4,002	$	2,231	$	933	$	4,142	$	2,197	$	935

For the three months ended July 29, 2016, consolidated net sales in the U.S. decreased 3 percent, non-U.S. developed markets increased 2 percent, and emerging markets net sales growth remained flat compared to the same period in the prior fiscal year. Our performance in the three months ending July 31, 2015, was favorably impacted by approximately $450 million due to an additional selling week as a result of our 52/53 week fiscal year calendar. Currency translation had an unfavorable impact of $7 million on net sales for the three months ended July 29, 2016.

COSTS AND EXPENSES

The following is a summary of major costs and expenses as a percent of net sales:



	Three months ended
	July 29, 2016		July 31, 2015
Cost of products sold	31.6	%	33.8	%
Research and development expense	7.8		7.7
Selling, general, and administrative expense	33.9		33.7

Cost of Products Sold We continue to focus on reducing our costs of production through channel optimization, supply chain management, and review of our manufacturing network.

Cost of products sold for the three months ended July 29, 2016 and July 31, 2015 were $2.3 billion and $2.5 billion, respectively. For the three months ended July 29, 2016, cost of products sold as a percent of net sales decreased 2.2 percentage points as compared to the same period in the prior fiscal year. The decrease in cost of products sold as a percentage of net sales over the same period in the prior fiscal year was primarily attributable to a $226 million charge during the first quarter of fiscal year 2016 related to amortization of the remaining Covidien inventory fair value adjustment.

Research and Development Expense We remain committed to accelerating the development of meaningful innovations to deliver better patient outcomes at appropriate costs, that lead to enhanced quality of life, and can be validated by clinical and economic evidence. We are also focused on expanding access to quality healthcare. During the first quarter of fiscal year 2017, we continued to invest in new technologies to support our mission with new acquisitions, as well as continued product growth within our business units.

Research and development expense for the three months ended July 29, 2016 and July 31, 2015 was $556 million and $558 million, respectively. Research and development expense remained consistent as a percentage of net sales over same period in the prior fiscal year.

Selling, General, and Administrative Expense Our goal is to continue to leverage selling, general, and administrative expense initiatives and to continue to realize cost synergies expected from our acquisitions.

Selling, general and administrative expense for both the three months ended July 29, 2016 and July 31, 2015 was $2.4 billion. Selling, general, and administrative expense remained consistent as a percentage of net sales over the same period in the prior fiscal year. We continue to execute on our cost synergies from the Covidien acquisition and remain on track to deliver synergy savings this fiscal year.

The following is a summary of other costs and expenses:



	Three months ended
(in millions)	July 29, 2016		July 31, 2015
Restructuring charges, net	$	94	$	67
Certain litigation charges	82		—
Acquisition-related items	52		71
Amortization of intangible assets	487		481
Other expense, net	39		61
Interest expense, net	179		191

Restructuring Charges, Net We incur restructuring charges in connection with our cost-reduction and productivity initiatives or with acquisitions when we implement plans to restructure and integrate the acquired operations. Amounts recognized as restructuring charges result from a series of judgments and estimates about future events and uncertainties and rely heavily on assumptions upon implementation of the initiative programs.

We began our restructuring program related to the integration of Covidien, the cost synergies initiative, in the fourth quarter of fiscal year 2015. We anticipate approximately $850 million in cost synergies to be achieved through fiscal year 2018, including administrative office optimization, manufacturing and supply chain infrastructure, and certain general and administrative savings. Restructuring charges are expected to be primarily related to employee termination costs and costs related to manufacturing and facility closures.

The cost synergies initiative is our primary restructuring program with a total liability of $256 million at July 29, 2016. During the three months ended July 29, 2016, we incurred $111 million in restructuring charges related to the cost synergies initiative, with $10 million recorded within cost of sales. These restructuring charges were partially offset by a $7 million reversal of excess restructuring reserves related to charges incurred in prior periods.

Restructuring programs affect the comparability of our operating results between periods, and we consider this a Non-GAAP Adjustment, refer to the "Executive Level Overview" section of this Management's Discussion and Analysis. For additional information, see Note 4 to the current period's consolidated financial statements.

Certain Litigation Charges We classify material litigation charges and gains recognized as certain litigation charges, net. Certain litigation charges, net will affect the comparability of our operating results between periods, and we consider this a Non-GAAP Adjustment, refer to the "Executive Level Overview" section of this Management's Discussion and Analysis.

During the three months ended July 29, 2016, we recognized $82 million of litigation charges related to probable and estimable damages. During the three months ended July 31, 2015, there were no certain litigation charges.

Acquisition-Related Items During the three months ended July 29, 2016 and July 31, 2015, we recognized acquisition-related items expense of $52 million and $71 million, respectively, primarily due to integration-related costs incurred in connection with the Covidien acquisition. Acquisition-related items affect the comparability of our operating results between periods, and we consider this a Non-GAAP Adjustment, refer to the "Executive Level Overview" section of this Management's Discussion and Analysis. See Note 3 to the current period's consolidated financial statements for additional information.

Amortization of Intangible Assets Amortization of intangible assets includes the amortization expense of our definite-lived intangible assets consisting of purchased patents, trademarks, tradenames, purchased technology, and other intangible assets. For the three months ended July 29, 2016 and July 31, 2015, amortization expense was $487 million and $481 million, respectively. Amortization of intangible assets affects the comparability of our operating results between periods, therefore we consider this a Non-GAAP Adjustment, refer to the "Executive Level Overview" section of this Management's Discussion and Analysis for further details related to this expense.

Other Expense, Net Other expense, net includes royalty income and expense, realized equity security gains and losses, realized currency transaction and derivative gains and losses, impairment charges on equity securities, and the Puerto Rico excise tax.

For the three months ended July 29, 2016, other expense, net was $39 million as compared to $61 million for the same period in the prior fiscal year. For the three months ended July 29, 2016, currency exchange gains decreased approximately $55 million offset by the cost savings related to the suspension of the U.S. medical device excise tax.

Interest Expense, Net Interest expense, net includes interest earned on our cash, cash equivalents and investments, interest incurred on our outstanding borrowings, amortization of debt issuance costs and debt discounts, the net realized and unrealized gain or loss on trading securities, ineffectiveness on interest rate derivative instruments, and the net realized gain or loss on the sale or impairment of available-for-sale debt securities.

For the three months ended July 29, 2016, interest expense, net was $179 million as compared to $191 million for the same period of the prior fiscal year. The decrease in interest expense, net during the three months ended July 29, 2016 was primarily driven by lower outstanding borrowings compared to the same period of the prior fiscal year.

INCOME TAXES



	Three months ended
(in millions)	July 29, 2016			July 31, 2015
Provision for income taxes	$	59		$	120
Income from operations before taxes	$	988		$	940
Effective tax rate	6.0		%	12.8		%

Non-GAAP provision for income taxes	$	269		$	323
Non-GAAP income from operations before taxes	$	1,713		$	1,785
Non-GAAP Nominal Tax Rate	15.7		%	18.1		%
Difference between the effective tax rate and Non-GAAP Nominal Tax Rate	9.7		%	5.3		%

The 6.8 percent decrease in the effective tax rate for the three months ended July 29, 2016, as compared to the three months ended July 31, 2015, was primarily due to the certain tax adjustments recorded during the three months ended July 29, 2016 and the impact from operational tax adjustments described below.

The 2.4 percent decrease in our Non-GAAP Nominal Tax Rate, as compared to the three months ended July 31, 2015, was primarily due to the finalization of certain tax returns and changes to uncertain tax position reserves. An increase in our Non-GAAP Nominal Tax Rate of 1 percent would result in an additional income tax provision for the three months ended July 29, 2016 of approximately $17 million.

Certain Tax Adjustments During the three months ended July 29, 2016, we recognized a $31 million net benefit from certain tax adjustments. A $431 million tax benefit was recognized as the result of the resolution of Covidien's previously disclosed Tyco International plc intercompany debt issues with the U.S. Tax Court and the Appeals Division of the IRS. The benefit was partially offset by a $371 million charge associated with the expected resolution with the IRS for the Ardian, CoreValve, Inc. and Ablation Frontiers, Inc. acquisition-related issues and the allocation of income between Medtronic, Inc. and its wholly owned subsidiary operating in Puerto Rico for certain businesses. This resolution does not include the businesses that are the subject of the Medtronic, Inc. U.S. Tax Court case for fiscal years 2005 and 2006. In addition, a $29 million charge was recognized in connection with the redemption of an intercompany minority interest. During the three months ended July 31, 2015, there were no certain tax adjustments.

See Notes 10 and 15 to the current period's consolidated financial statements for additional information.

LIQUIDITY AND CAPITAL RESOURCES



(in millions)	July 29, 2016			April 29, 2016
Working capital	$	15,602		$	16,435
Current ratio ⁽¹⁾	3.0:1.0			3.3:1.0
Cash, cash equivalents, and current investments	$	12,810		$	12,634
Current debt obligations and long-term debt	32,071			31,102
Net cash position ⁽²⁾	$	(19,261	)	$	(18,468	)
Total shareholders' equity	$	50,824		$	52,063
Debt-to-total capital ratio ⁽³⁾	39		%	37		%


(1)	The ratio of current assets to current liabilities.


(2)	The sum of cash, cash equivalents, and current investments less current debt obligations and long-term debt and excludes non-current investments that are not considered readily available to fund current operations.


(3)	The ratio of total debt (current debt obligations and long-term debt) to total capitalization (total debt and total shareholders' equity).

We believe our balance sheet and liquidity provide us with flexibility in the future. Approximately $5 billion of our cash, cash equivalents, and investments held by certain U.S.-controlled non-U.S. subsidiaries may not represent available liquidity for general corporate purposes. However, we believe our other existing cash, cash equivalents and investments, as well as our $3.5 billion revolving credit facility and related commercial paper program ($975 million of commercial paper outstanding at July 29, 2016), will satisfy our foreseeable working capital requirements for at least the next 12 months. We regularly review our capital needs and consider various investing and financing alternatives to support our requirements.

Our net cash position at July 29, 2016 decreased by $655 million as compared to April 29, 2016. See the “Summary of Cash Flows” section of this management’s discussion and analysis for further information.



	Agency Rating ⁽¹⁾
	July 29, 2016	April 29, 2016
Standard & Poor's Ratings Services
Long-term debt	A	A
Short-term debt	A-1	A-1

Moody's Investors Service
Long-term debt	A3	A3
Short-term debt	P-2	P-2

(1) Agency ratings are subject to change, and there can be no assurance that a ratings agency will continue to provide ratings and/or

maintain its current ratings. A security rating is not a recommendation to buy, sell or hold securities, and may be subject to revision or

withdrawal at any time by the rating agency, and each rating should be evaluated independently of any other rating.

Standard & Poor's Ratings Services (S&P) and Moody's Investors Service (Moody's) long-term debt rating and short-term debt rating at July 29, 2016 were unchanged as compared to the ratings at April 29, 2016. We do not expect the S&P and Moody's Ratings Services' ratings to have a significant impact on our liquidity or future flexibility to access additional liquidity given our balance sheet, and our $3.5 billion revolving credit facility and related commercial paper program, discussed above and within the “Debt and Capital” section of this management's discussion and analysis.

We have future contractual obligations and other minimum commercial commitments that are entered into in the normal course of business. We believe our off-balance sheet arrangements do not have a material current or anticipated future effect on our consolidated earnings, financial position, and/or cash flows.

Note 15 to the consolidated financial statements provides information regarding amounts we have accrued related to significant legal proceedings. In accordance with U.S. GAAP, we record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. Actual settlements may be different than estimated and could have a material impact on our consolidated earnings, financial position, and/or cash flows.

We provide for tax liabilities in our financial statements with respect to amounts that we expect to repatriate from subsidiaries (to the extent the repatriation would be subject to tax); however, no tax liabilities are recorded for amounts that we consider to be permanently reinvested. Our current plans do not foresee a need to repatriate funds that are designated as permanently reinvested in order to fund our operations or meet currently anticipated liquidity and capital investment needs. However, we evaluate our legal entity structure supporting our business operations, and to the extent such evaluation results in a change to our overall business structure, we may be required to accrue for additional tax obligations.

We have investments in marketable debt securities that are classified and accounted for as available-for-sale. Our debt securities include U.S. government and agency securities, corporate debt securities, mortgage-backed securities, other asset-backed securities, debt funds, and auction rate securities. Some of our investments may experience reduced liquidity due to changes in market conditions and investor demand. Our auction rate security holdings continue to experience reduced liquidity due to low investor demand. Although our auction rate securities are currently illiquid and other securities could become illiquid, we believe we could liquidate a substantial amount of our portfolio without incurring a material impairment loss.

For the three months ended July 29, 2016, the total other-than-temporary impairment losses on available-for-sale debt securities were not significant. Based on our assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which we are invested, we believe we have recorded all necessary other-than-temporary impairments as we do not have the intent to sell, nor is it more likely than not that we will be required to sell, before recovery of the amortized cost. However, at July 29, 2016, we have $279 million of gross unrealized losses on our aggregate current and non-current available-for-sale debt securities of $9.7 billion; if market conditions deteriorate, some of these holdings may experience other-than-temporary impairment in the future which could adversely impact our financial results. Management is required to use estimates and assumptions in its valuation of our investments, which requires a high degree of judgment, and therefore, actual results could differ materially from those estimates. See Note 5 to the current period's consolidated financial statements for additional information regarding fair value measurements.

Summary of Cash Flows



	Three months ended
(in millions)	July 29, 2016			July 31, 2015
Cash provided by (used in):
Operating activities	$	1,550		$	816
Investing activities	(284		)	(986		)
Financing activities	(1,160		)	(1,744		)
Effect of exchange rate changes on cash and cash equivalents	78			50
Net change in cash and cash equivalents	$	184		$	(1,864	)

Operating Activities The $734 million increase was primarily driven by a decrease in cash paid for incomes taxes of $521 million and an increase in net income before net noncash charges of $117 million. The decrease in cash paid for income taxes was primarily a result of payments made for the resolution of the Kyphon acquisition-related matters, as well as Covidien income tax extension payments, during the three months ended July 31, 2015. We did not make any significant audit settlement payments or significant extension payments during the three months ended July 29, 2016.

Investing Activities The $702 million decrease in net cash used was primarily attributable to lower levels of cash used for purchases of investments and acquisitions, partially offset by proceeds from the sale of investments and increased capital expenditures.

Financing Activities The $584 million decrease in net cash used primarily resulted from a net increase in our debt obligations, partially offset by an increase in share repurchases.

Free Cash Flow

Free cash flow, a non-GAAP financial measure, is calculated by subtracting property, plant, and equipment additions from operating cash flows. Management uses this non-GAAP financial measure, in addition to U.S. GAAP financial measures to evaluate our operating results. Free cash flow should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. Reconciliations between net cash provided by operating activities (the most comparable U.S. GAAP measure) and free cash flow are as follows:



	Three months ended
(in millions)	July 29, 2016			July 31, 2015
Net cash provided by operating activities	$	1,550		$	816
Net cash used in investing activities	(284		)	(986		)
Net cash used in financing activities	(1,160		)	(1,744		)

Net cash provided by operating activities	1,550			816
Additions to property, plant, and equipment	(330		)	(224		)
Free cash flow	$	1,220		$	592

Dividends to shareholders	599			538
Repurchase of ordinary shares	1,763			750
Issuances of ordinary shares	(214		)	(98		)
Return to shareholders	$	2,148		$	1,190
Return of operating cash flow percentage	139		%	146		%
Return of free cash flow percentage	176		%	201		%

Debt and Capital

Our capital structure consists of equity and interest-bearing debt. Interest-bearing debt as a percentage of total interest-bearing debt and equity was 39 percent and 37 percent at July 29, 2016 and April 29, 2016, respectively.

As part of our focus on returning value to our shareholders, shares are repurchased from time to time. In June 2015, the Company's Board of Directors authorized, subject to the ongoing existence of sufficient distributable reserves, the redemption of 80 million of the Company's ordinary shares. During the three months ended July 29, 2016, we repurchased approximately 20.7 million shares, at an average price per share of $85.06. At July 29, 2016, we had approximately 51.2 million shares remaining under share repurchase programs authorized by our Board of Directors.

We use a combination of bank borrowings and commercial paper issuances to fund our short-term financing needs. Current debt obligations, including the current portion of our long-term debt and capital lease obligations, at July 29, 2016, was $1.9 billion compared to $993 million at April 29, 2016. We utilize Senior Notes to meet our long-term financing needs. Long-term debt at July 29, 2016 was $30.1 billion compared to $30.1 billion at April 29, 2016.

We maintain a commercial paper program for short term financing, which allows us to issue unsecured commercial paper notes on a private placement basis up to a maximum aggregate amount outstanding at any time of $3.5 billion. At July 29, 2016, we had $975 million of commercial paper outstanding. No amount of commercial paper was outstanding at April 29, 2016. During the three months ended July 29, 2016, the weighted average original maturity of the commercial paper outstanding was approximately 21 days, and the weighted average interest rate was 0.73 percent. The issuance of commercial paper reduced the amount of credit available under our revolving credit facility.

We also have a $3.5 billion syndicated line of credit facility ($3.5 Billion Revolving Credit Facility) which expires in January 2020. The $3.5 Billion Revolving Credit Facility provides backup funding for the commercial paper program and may also be used for general corporate purposes. The $3.5 Billion Revolving Credit Facility provides us with the ability to increase its borrowing capacity by an additional $500 million at any time during the term of the agreement. At each anniversary date of the $3.5 Billion Revolving Credit Facility, but not more than twice prior to the maturity date, we could also request a one-year extension of the maturity date. At July 29, 2016 and April 29, 2016, no amounts were outstanding on the committed line of credit.

Interest rates on advances of our $3.5 Billion Revolving Credit Facility are determined by a pricing matrix, based on our long-term debt ratings assigned by S&P and Moody’s. For additional information on our credit ratings status by S&P and Moody's refer to "Liquidity and Capital Resources" section of this management's discussion and analysis. Facility fees are payable on the credit facility and are determined in the same manner as the interest rates. The agreements also contain customary covenants, all of which we remain in compliance with at July 29, 2016.

For more information on credit arrangements, see the "Liquidity and Capital Resources" section of this management discussion and analysis, Note 6 to the current period's consolidated financial statements, and Note 7 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended April 29, 2016.

CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS

This Quarterly Report on Form 10-Q, and other written reports and oral statements made by or with the approval of one of the Company’s executive officers from time to time, may include “forward-looking” statements. Forward-looking statements broadly include our current expectations or forecasts of future results. Our forward-looking statements generally relate to our growth and growth strategies, developments in the markets for our products, financial results, product development launches and effectiveness, research and development strategy, regulatory approvals, competitive strengths, restructuring and cost-saving initiatives, intellectual property rights, litigation and tax matters, government investigations, mergers and acquisitions, market acceptance of our products, accounting estimates, financing activities, ongoing contractual obligations, working capital adequacy, value of our investments, our effective tax rate, our expected returns to shareholders, and sales efforts. Such statements can be identified by the use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “looking ahead,” “may,” “plan,” “possible,” “potential,” “project,” “should,” “will,” and similar words or expressions. Forward-looking statements in this Quarterly Report include, but are not limited to, statements regarding our ability to drive long-term shareholder value, development and future launches of products and continued or future acceptance of products and therapies in our operating segments; market positioning and performance of our products, including stabilization of certain product markets; anticipated timing for U.S. FDA and non-U.S. regulatory approval of new products; increased presence in new markets, including markets outside the U.S.; changes in the market and our market share; acquisitions and investment initiatives, as well as integration of acquired companies into our operations; the resolution of tax matters; the effectiveness of our development activities in reducing patient care costs and hospital stay lengths; our approach towards cost containment; our expectations regarding health care costs, including potential changes to reimbursement policies and pricing pressures; our expectations regarding changes to patient standards of care; our ability to identify and maintain successful business partnerships; the elimination of certain positions or costs related to restructuring initiatives; outcomes in our litigation matters and government investigations; general economic conditions; the adequacy of available working capital and our working capital needs; our payment of dividends and redemption of shares; the continued strength of our balance sheet and liquidity; our accounts receivable exposure; and the potential impact of our compliance with governmental regulations and accounting guidance. One must carefully consider forward-looking statements and understand that such statements may be affected by inaccurate assumptions and may involve a variety of risks and uncertainties, known and unknown, including, among others, risks related to competition in the medical device industry, reduction or interruption in our supply, quality problems, liquidity shortfalls, decreasing prices and pricing pressure, fluctuations in currency exchange rates, changes in applicable tax rates, positions taken by taxing authorities, adverse regulatory action, delays in regulatory approvals, litigation results, self-insurance, commercial insurance, health care policy changes, international operations, failure to complete or achieve the intended benefits of acquisitions or disruption of our current plans and operations, as well as those discussed in the sections entitled “Risk Factors” and “Government Regulation and Other Considerations” in our Annual Report on Form 10-K for the year ended April 29, 2016. Consequently, no forward-looking statement can be guaranteed and actual results may vary materially. We intend to take advantage of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding our forward-looking statements, and are including this sentence for the express purpose of enabling us to use the protections of the safe harbor with respect to all forward-looking statements.

We undertake no obligation to update any statement we make, but investors are advised to consult all other disclosures by us in our filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q, and 8-K, in which we discuss in more detail various important factors that could cause actual results to differ from expected or historical results. In addition, actual results may differ materially from those anticipated due to a number of factors, including, among others, those discussed in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended April 29, 2016. It is not possible to foresee or identify all such factors. As such, investors should not consider any list of such factors to be an exhaustive statement of all risks, uncertainties, or potentially inaccurate assumptions.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Currency Exchange Rate Risk

Due to the global nature of our operations, we are exposed to currency exchange rate changes. In a period where the U.S. dollar is strengthening/weakening as compared to other currencies, our revenues and expenses denominated in other currencies are translated into U.S. dollars at a lower/higher value than they would be in an otherwise constant currency exchange rate environment.

We use operational and economic hedges, as well as currency exchange rate derivative instruments, to manage the impact of currency exchange rate fluctuations on earnings and cash flows. In order to minimize earnings and cash flow volatility resulting from currency exchange rate fluctuations, we enter into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative instrument is designated as either a freestanding derivative or a cash flow hedge. The primary currencies of the derivative instruments are the Euro and Japanese Yen. Fluctuations in the currency exchange rates of currency exposures that are unhedged, such as in certain emerging markets, may result in future earnings and cash flow volatility. We do not enter into currency exchange rate derivative instruments for speculative purposes.

The gross notional amount of all currency exchange rate derivative instruments outstanding at July 29, 2016 and April 29, 2016 was $10.7 billion and $10.8 billion, respectively. At July 29, 2016, these contracts were in an unrealized gain position of $104 million. A sensitivity analysis of changes in the fair value of all currency exchange rate derivative contracts at July 29, 2016 indicates that, if the U.S. dollar uniformly strengthened/weakened by 10 percent against all currencies, the fair value of these contracts would increase/decrease by approximately $768 million. Any gains and losses on the fair value of derivative contracts would generally be offset by gains and losses on the underlying transactions. These offsetting gains and losses are not reflected in the above analysis.

Interest Rate Risk

We are subject to interest rate risk on our short-term investments and our borrowings. We manage interest rate risk in the aggregate, while focusing on our immediate and intermediate liquidity needs. Our debt portfolio as of July 29, 2016, was comprised of debt predominately denominated in U.S. dollars, of which approximately 90% is fixed rate debt and approximately 10% is floating-rate debt. We are also exposed to interest rate changes affecting our investments in interest rate sensitive instruments, which include our marketable debt securities, fixed-to-floating interest rate swap agreements, and forward starting interest rate swap agreements.

A sensitivity analysis of the impact on our investments in interest rate sensitive financial instruments of a hypothetical 10 basis point change in interest rates, compared to interest rates as of July 29, 2016, indicates that the fair value of these instruments would correspondingly change by $59 million.

For a discussion of current market conditions and the impact on our financial condition and results of operations, see the “Liquidity and Capital Resources” section of the current period's management's discussion and analysis. For additional discussion of market risk, see Notes 5 and 7 to the current period's consolidated financial statements.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) and changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this quarterly report, our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) are effective.

Changes in internal control over financial reporting

As previously disclosed, the Company is deploying an enterprise resource planning (ERP) software platform, SAP, to the Minimally Invasive Therapies Group. During the first quarter of fiscal year 2017, Medtronic began deployment of this software along with other enterprise systems, which resulted in a material change to the internal controls over financial reporting for Minimally Invasive Therapies Group. The internal controls were updated to reflect these changes. These system deployments will continue with projected completion by the end of fiscal year 2018. There have been no other changes in our internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act) during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

A discussion of the Company’s policies with respect to legal proceedings is included in the management’s discussion and analysis and our legal proceedings and other loss contingencies are described in Note 15 to the current period's consolidated financial statements.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

The following table provides information about the shares repurchased by the Company during the first quarter of fiscal year 2017:



Fiscal Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as a Part of Publicly Announced Program (1)	Maximum Number of Shares that may yet be Purchased Under the Program (1)
4/30/2016-5/27/2016	5,530,372	$	80.46	5,530,372	66,348,369
5/28/2016-7/1/2016	5,284,983	84.20		5,284,983	61,063,386
7/2/2016-7/29/2016	9,912,472	88.08		9,912,472	51,150,914
Total	20,727,827	$	85.06	20,727,827	51,150,914


(1)	In June 2015, the Company’s Board of Directors authorized, subject to the ongoing existence of sufficient distributable reserves, the repurchase of 80 million of the Company’s ordinary shares. As authorized by the Board of Directors, our share redemption program expires when the total number of authorized shares have been redeemed.

Item 6. Exhibits



(a)	Exhibits
	10.1	Letter Agreement by and between Medtronic plc and Karen Parkhill (incorporated by reference to Exhibit 10.1 to Medtronic plc’s Current Report on Form 8-K, filed on May 4, 2016, File No. 001-36820).
	31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
	31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
	32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
	32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
	101.INS	XBRL Instance Document
	101.SCH	XBRL Schema Document
	101.CAL	XBRL Calculation Linkbase Document
	101.DEF	XBRL Definition Linkbase Document
	101.LAB	XBRL Label Linkbase Document
	101.PRE	XBRL Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



		MEDTRONIC PUBLIC LIMITED COMPANY
		(Registrant)

Date:	September 7, 2016	/s/ Omar Ishrak
		Omar Ishrak
		Chairman and Chief Executive Officer

Date:	September 7, 2016	/s/ Karen L. Parkhill
		Karen L. Parkhill
		Executive Vice President and
		Chief Financial Officer

Attached files

Medtronic plc Reports

Also read